Ibrutinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Ibrutinib comprises 426 peer-reviewed publications across 15 journals, 42 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, and Bronchiolitis Obliterans Syndrome. Most recent publication: Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM)., Dermatol Ther (Heidelb), 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction.
    Tapaninen T, Olkkola AM, Tornio A, et al. · Clin Transl Sci · 2021
    PubMed: PMID 31664782 · NCT05348096 · Bronchiolitis Obliterans Syndrome
  2. Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
    Stewart DA, Kuruvilla J, Lee D, et al. · Br J Haematol · 2024
    PubMed: PMID 38802107 · NCT02436707 · Lymphoma
  3. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    Moreno C, Greil R, Demirkan F, et al. · Lancet Oncol · 2020
    PubMed: PMID 30522969 · NCT02264574 · Leukemia, Lymphocytic, Chronic, B-Cell
  4. Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.
    Langerbeins P, Robrecht S, Nieper P, et al. · J Clin Oncol · 2025
    PubMed: PMID 39602678 · NCT02863718 (CLL12) · Leukemia, Lymphocytic, Chronic, B-Cell
  5. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Fürstenau M, Kater AP, Robrecht S, et al. · Lancet Oncol · 2024
    PubMed: PMID 38821083 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  6. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
    Eichhorst B, Niemann CU, Kater AP, et al. · N Engl J Med · 2023
    PubMed: PMID 37163621 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  7. CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence.
    Blasiak A, Khong J, Kee T, et al. · SLAS Technol · 2021
    PubMed: PMID 31771394 · NCT04522284 · Waldenstrom Macroglobulinemia
  8. Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
    Alcantara M, Chevrier M, Jardin F, et al. · J Hematol Oncol · 2024
    PubMed: PMID 39300447 · NCT04446962 (LOC-R01) · Lymphoma, Large B-Cell, Diffuse

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01578707
RESONATE™
Leukemia, Lymphocytic, Chronic, B-CellPFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013
Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.
Ibrutinib (Arm B)NA months
Ofatumumab (Arm A)8.1 months
NCT01611090Leukemia, Lymphocytic, Chronic, B-CellProgression-free Survival (PFS)
Up to 5 years
Ibrutinib+BR65.12 Months
Placebo+BR14.32 Months
NCT01646021Lymphoma, Mantle-CellProgression Free Survival (PFS)
Time from the date of randomization until the date of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death, whichever occurred first (approximately 48 months)
Ibrutinib15.6 Months
Temsirolimus6.2 Months
NCT01722487Leukemia, Lymphocytic, Chronic, B-CellPFS (Progression Free Survival)
Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Chlorambucil18.9 Months
IbrutinibNA Months
NCT01724346Leukemia, Lymphocytic, Chronic, B-CellProgression Free Survival (PFS) Based on Investigator Assessment
Median overall follow-up of 82.7 months
Chlorambucil15.0 months
Ibrutinib106.9 months
NCT01776840Lymphoma, Mantle-CellProgression-free Survival (PFS)
Up to 97 months
Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)80.6 months
Placebo + Bendamustine and Rituximab (BR) (Treatment A)52.9 months
NCT01855750Lymphoma, Large B-Cell, DiffuseEvent-Free Survival (EFS) - Activated B-Cell (ABC) Population
Up to approximately 4.5 years
Treatment Arm A: Placebo+R-CHOP48.16 Months
Treatment Arm B: Ibrutinib+R-CHOP48.56 Months
NCT01855750Lymphoma, Large B-Cell, DiffuseEvent-Free Survival (EFS) - Intent-to-Treat (ITT) Population
Up to 5.5 years
Treatment Arm A: Placebo+R-CHOP54.77 Months
Treatment Arm B: Ibrutinib+R-CHOP49.64 Months
NCT01886872Leukemia, Lymphocytic, Chronic, B-CellProgression Free Survival (PFS)
Time from study entry to the time of documented disease progression or death. The analysis was event driven, performed at 2.5 years after the last patient enrolled;up to 4 years.
Arm A (Rituximab, Bendamustine Hydrochloride)43 months
Arm B (Ibrutinib)NA months
Arm C (Ibrutinib, Rituximab)NA months
NCT01973387Leukemia, Lymphocytic, Chronic, B-CellProgression-free Survival (PFS)
From the date of randomization to the date of disease progression or death, whichever was first reported (Up to 3.7 years)
IbrutinibNA months
Rituximab8.38 months
NCT01974440
SELENE
LymphomaPrimary Analysis: Progression Free Survival (PFS): Stratified Analysis
Up to 8 years
Ibrutinib + CIT40.51 months
Placebo + Chemoimmunotherapy (CIT)23.75 months
NCT01974440
SELENE
LymphomaSupplementary Analysis: Progression Free Survival: Unstratified Analysis - Participants With Marginal Zone Lymphoma (MZL)
Up to 8 years
Ibrutinib + CITNA months
Placebo + Chemoimmunotherapy (CIT)91.63 months
NCT02048813Leukemia, Lymphocytic, Chronic, B-CellProgression-free Survival (PFS) Rate at 3 Years
Assessed every 3 months until progression up to 4 years and 8 months
Arm A (Ibrutinib, Rituximab)0.894 Proportion of participants
Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide)0.729 Proportion of participants
NCT02165397LymphomaProgression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54
Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])
Ibrutinib + Rituximab68.0 percentage of participants
Open-Label Substudy: Ibrutinib39.7 percentage of participants
Placebo + Rituximab25.3 percentage of participants
NCT02264574Leukemia, Lymphocytic, Chronic, B-CellFinal Analysis: PFS Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48
Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).
CLB+OB22.0 percentage of participants
IBR+OB74.0 percentage of participants
NCT02264574Leukemia, Lymphocytic, Chronic, B-CellPrimary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30
Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).
CLB+OB31.1 percentage of participants
IBR+OB78.5 percentage of participants
NCT02301156
GENUINE
Leukemia, Lymphocytic, Chronic, B-CellOverall Response Rate (ORR)
Up to 62 months
Ibrutinib69.4 percentage of participants
Ublituximab + Ibrutinib84.4 percentage of participants
NCT02436668—Overall Survival (OS)
Results at an overall median follow-up of 24.87 months
Ibrutinib+Gemcitabine+Nab-paclitaxel9.69 Months
Placebo+Gemcitabine+Nab-Paclitaxel10.78 Months
NCT02436668—Progression Free Survival (PFS)
Results at an overall median follow-up of 24.87 months
Ibrutinib+Gemcitabine+Nab-paclitaxel5.32 Months
Placebo+Gemcitabine+Nab-Paclitaxel6.01 Months
NCT02443077—24-month Progression-free Survival (PFS), Defined as the Proportion of Patients Who Are Alive and Progression-free 2 Years From Randomization
Time between registration and disease progression or death, whichever comes first, assessed at 24 months
Arm I (Ibrutinib, Chemotherapy, autoHCT)0.576 proportion of participants
Arm II (Placebo, Chemotherapy, autoHCT)0.408 proportion of participants
NCT02477696Leukemia, Lymphocytic, Chronic, B-CellProgression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment
Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)
Acalabrutinib38.4 Months
Ibrutinib38.4 Months
NCT02703272Lymphoma, Non-HodgkinPart 1: Apparent (Oral) Plasma Clearance (CL/F) of Ibrutinib
Up to Cycle 3 (each cycle of 21 or 28 days)
Part 1: Ibrutinib: 240 mg/m^2348 milliliter per hour (mL/h)
Part 1: Ibrutinib: 240 mg/m^21450 milliliter per hour (mL/h)
Part 1: Ibrutinib: 240 mg/m^21220 milliliter per hour (mL/h)
Part 1: Ibrutinib: 329 mg/m^2508 milliliter per hour (mL/h)
Part 1: Ibrutinib: 329 mg/m^2729 milliliter per hour (mL/h)
Part 1: Ibrutinib: 329 mg/m^2805 milliliter per hour (mL/h)
Part 1: Ibrutinib: 440 mg/m^21200 milliliter per hour (mL/h)
Part 1: Ibrutinib: 440 mg/m^21300 milliliter per hour (mL/h)
NCT02703272Lymphoma, Non-HodgkinPart 1: Apparent (Oral) Volume of Distribution (Vd/F) of Ibrutinib
Up to Cycle 3 (each cycle of 21 or 28 days)
Part 1: Ibrutinib: 240 mg/m^211.1 liter(s)
Part 1: Ibrutinib: 240 mg/m^218 liter(s)
Part 1: Ibrutinib: 240 mg/m^23.63 liter(s)
Part 1: Ibrutinib: 329 mg/m^27.55 liter(s)
Part 1: Ibrutinib: 329 mg/m^211.3 liter(s)
Part 1: Ibrutinib: 329 mg/m^25.18 liter(s)
Part 1: Ibrutinib: 440 mg/m^219 liter(s)
Part 1: Ibrutinib: 440 mg/m^27.63 liter(s)
NCT02703272Lymphoma, Non-HodgkinPart 1: Area Under the Plasma Concentration-time Curve (AUC) of Ibrutinib
Up to Cycle 3 (each cycle of 21 or 28 days)
Part 1: Ibrutinib: 240 mg/m^2145 hours*nanogram per milliliter (h*ng/mL)
Part 1: Ibrutinib: 240 mg/m^21210 hours*nanogram per milliliter (h*ng/mL)
Part 1: Ibrutinib: 240 mg/m^2143 hours*nanogram per milliliter (h*ng/mL)
Part 1: Ibrutinib: 329 mg/m^2386 hours*nanogram per milliliter (h*ng/mL)
Part 1: Ibrutinib: 329 mg/m^2349 hours*nanogram per milliliter (h*ng/mL)
Part 1: Ibrutinib: 329 mg/m^2661 hours*nanogram per milliliter (h*ng/mL)
Part 1: Ibrutinib: 440 mg/m^2324 hours*nanogram per milliliter (h*ng/mL)
Part 1: Ibrutinib: 440 mg/m^2310 hours*nanogram per milliliter (h*ng/mL)
NCT02703272Lymphoma, Non-HodgkinPart 1: Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
Up to Cycle 3 (each cycle of 21 or 28 days)
Part 1: Ibrutinib: 240 mg/m^24.88 nanograms per milliliter (ng/mL)
Part 1: Ibrutinib: 240 mg/m^23.86 nanograms per milliliter (ng/mL)
Part 1: Ibrutinib: 240 mg/m^23.46 nanograms per milliliter (ng/mL)
Part 1: Ibrutinib: 329 mg/m^24.48 nanograms per milliliter (ng/mL)
Part 1: Ibrutinib: 329 mg/m^24.73 nanograms per milliliter (ng/mL)
Part 1: Ibrutinib: 329 mg/m^23.64 nanograms per milliliter (ng/mL)
Part 1: Ibrutinib: 440 mg/m^25.07 nanograms per milliliter (ng/mL)
Part 1: Ibrutinib: 440 mg/m^23.88 nanograms per milliliter (ng/mL)
NCT02703272Lymphoma, Non-HodgkinPart 2: Event Free Survival (EFS) Between the 2 Treatment Groups
Time from Randomization to death, disease progression, or lack of CR or PR after 3 cycles of treatment (up to 4 year and 4 months)
Part 2: Chemoimmunotherapy6.97 Months
Part 2: Ibrutinib+CIT (RICE or RVICI)6.05 Months
NCT02801578Leukemia, Lymphocytic, Chronic, B-CellParticipants With >/= 95 % Bruton's Tyrosine Kinase (BTK) Occupancy
3 cycles, up to 90 days
Ibrutinib8 Participants
NCT02947347Lymphoma, Non-HodgkinProgression-Free Survival (PFS) as Assessed by Investigator
Primary Analysis cut-off; median overall follow-up of 53.75 months
Arm A: Ibrutinib + Rituximab42.02 months
Arm B: Placebo + Rituximab32.76 months
NCT02959944
iNTEGRATE
Bronchiolitis Obliterans SyndromeFinal Analysis: Response Rate at 48 Weeks
48 weeks (Cumulatively up to 12 July 2021)
Ibrutinib + Prednisone41.1 percentage of participants
Placebo + Prednisone36.7 percentage of participants
NCT02959944
iNTEGRATE
Bronchiolitis Obliterans SyndromePrimary Analysis: Response Rate at 48 Weeks
48 weeks (Cumulatively up to 30 March 2020)
Ibrutinib + Prednisone41.1 percentage of participants
Placebo + Prednisone36.7 percentage of participants
NCT03053440
ASPEN
Waldenstrom MacroglobulinemiaPercentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the Sixth International Workshop on WM as Assessed by an Independent Review Committee (IRC)
Up to approximately 2 years and 7 months
Arm A: Ibrutinib19.2 Percentage of Participants
Arm B: Zanubrutinib28.4 Percentage of Participants
NCT03112174
SYMPATICO
Lymphoma, Mantle-CellComplete Response (CR) Rate (Treatment-Naive Arm)
For an overall median time on study of 40.51 months
Treatment-naive Open-label Arm69.2 percentage of participants
NCT03112174
SYMPATICO
Lymphoma, Mantle-CellNumber of Participants With Dose Limiting Toxicities (DLT) (Safety Run-in)
After at least 3 months of treatment, with an overall median treatment duration of 20.0 months
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline3 Participants
Safety Run-in: Increased TLS Risk at Baseline3 Participants
Safety Run-in: Increased TLS Risk at Baseline0 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline0 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline0 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
NCT03112174
SYMPATICO
Lymphoma, Mantle-CellNumber of Participants With Treatment Emergent Adverse Events (TEAEs) (Safety Run-in)
From first dose of study drug until the end of treatment + 30 days, with an overall median treatment duration of 20.0 months
Safety Run-in: Increased TLS Risk at Baseline14 Participants
Safety Run-in: Increased TLS Risk at Baseline2 Participants
Safety Run-in: Increased TLS Risk at Baseline2 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline10 Participants
Safety Run-in: Increased TLS Risk at Baseline10 Participants
Safety Run-in: Increased TLS Risk at Baseline9 Participants
Safety Run-in: Increased TLS Risk at Baseline14 Participants
Safety Run-in: Increased TLS Risk at Baseline2 Participants
Safety Run-in: Increased TLS Risk at Baseline13 Participants
Safety Run-in: Increased TLS Risk at Baseline0 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline14 Participants
Safety Run-in: Increased TLS Risk at Baseline3 Participants
Safety Run-in: Increased TLS Risk at Baseline3 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline7 Participants
Safety Run-in: Increased TLS Risk at Baseline4 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Increased TLS Risk at Baseline6 Participants
Safety Run-in: Increased TLS Risk at Baseline12 Participants
Safety Run-in: Increased TLS Risk at Baseline13 Participants
Safety Run-in: Increased TLS Risk at Baseline13 Participants
Safety Run-in: Increased TLS Risk at Baseline14 Participants
Safety Run-in: Increased TLS Risk at Baseline15 Participants
Safety Run-in: Increased TLS Risk at Baseline15 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline1 Participants
Safety Run-in: Low TLS Risk at Baseline1 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline3 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline1 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline4 Participants
Safety Run-in: Low TLS Risk at Baseline1 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline3 Participants
Safety Run-in: Low TLS Risk at Baseline4 Participants
Safety Run-in: Low TLS Risk at Baseline2 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
Safety Run-in: Low TLS Risk at Baseline2 Participants
Safety Run-in: Low TLS Risk at Baseline4 Participants
Safety Run-in: Low TLS Risk at Baseline5 Participants
Safety Run-in: Low TLS Risk at Baseline4 Participants
Safety Run-in: Low TLS Risk at Baseline6 Participants
Safety Run-in: Low TLS Risk at Baseline5 Participants
Safety Run-in: Low TLS Risk at Baseline6 Participants
Safety Run-in: Low TLS Risk at Baseline3 Participants
Safety Run-in: Low TLS Risk at Baseline2 Participants
Safety Run-in: Low TLS Risk at Baseline1 Participants
NCT03112174
SYMPATICO
Lymphoma, Mantle-CellNumber of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in)
After at least 3 months of treatment, with an overall median treatment duration of 20.0 months
Safety Run-in: Increased TLS Risk at Baseline1 Participants
Safety Run-in: Low TLS Risk at Baseline0 Participants
NCT03112174
SYMPATICO
Lymphoma, Mantle-CellProgression-free Survival (PFS) (Randomization Phase)
For an overall median time on study of 61.34 months
Randomization Phase: Ibrutinb + Venetoclax31.9 months
Randomization Phase: Ibrutinib + Placebo22.1 months
NCT03112603Bronchiolitis Obliterans SyndromeEfficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit
Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
Best Available Therapy25.6 percentage of participants
Ruxolitinib49.7 percentage of participants
NCT03462719
GLOW
Leukemia, Lymphocytic, Chronic, B-CellProgression Free Survival (PFS)
Up to 2 years 10 months
Treatment Arm A (Ibrutinib + Venetoclax)NA Months
Treatment Arm B (Chlorambucil + Obinutuzumab)20.96 Months
NCT03474679Graft vs Host DiseaseOverall Response Rate (ORR)
Up to 3 year 6 months
Ibrutinib 420 mg84.2 Percentage of participants
NCT03734016
ALPINE
Leukemia, Lymphocytic, Chronic, B-CellORR Assessed by the Independent Review Committee (IRC)
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Ibrutinib75.7 percentage of participants
Zanubrutinib86.2 percentage of participants
NCT03734016
ALPINE
Leukemia, Lymphocytic, Chronic, B-CellOverall Response Rate (ORR) Assessed by the Investigator
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Ibrutinib74.2 percentage of participants
Zanubrutinib83.5 percentage of participants
NCT03737981Leukemia, Lymphocytic, Chronic, B-CellProgression-free Survival (PFS)
5 years
Arm I (Ibrutinib, Obinutuzumab)0.59 proportion of participants w/out event
Arm II (Ibrutinib, Obinutuzumab, Venetoclax)0.68 proportion of participants w/out event

Publications by year

1981–2026: 426 publications.

1981
1
1983
1
1988
1
1994
1
1995
1
1996
3
1997
2
1999
2
2000
4
2001
6
2002
4
2003
8
2004
3
2005
7
2006
14
2007
12
2008
13
2009
8
2010
6
2011
13
2012
12
2013
18
2014
13
2015
17
2016
16
2017
12
2018
11
2019
32
2020
15
2021
40
2022
33
2023
30
2024
29
2025
24
2026
14

Publications by indication

Leukemia, Lymphocytic, Chronic, B-Cell (123)

  • Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    J Clin Oncol · 2026 · PMID 41353787 · NCT05254743
  • Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.
    EClinicalMedicine · 2026 · PMID 41497516 · NCT03980002
  • Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial.
    Curr Med Res Opin · 2026 · PMID 41686056 · NCT03734016
  • Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.
    Blood · 2026 · PMID 41911073 · NCT02950051
  • Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Cancers (Basel) · 2026 · PMID 41749915 · NCT05254743

Lymphoma, Mantle-Cell (91)

  • Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.
    Blood Adv · 2026 · PMID 41380113 · NCT02471391
  • Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
    Lancet · 2026 · PMID 42134356 · NCT02858258
  • Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Oncol · 2025 · PMID 39914418 · NCT03112174
  • First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients.
    Hematol Oncol · 2025 · PMID 40517546 · NCT06482684
  • A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis.
    Blood Adv · 2024 · PMID 37939259 · NCT02927964

Lymphoma, Large B-Cell, Diffuse (57)

  • Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas.
    Blood Neoplasia · 2026 · PMID 41536778 · NCT03876028
  • Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
    J Hematol Oncol · 2024 · PMID 39300447 · NCT04446962
  • Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
    N Engl J Med · 2024 · PMID 38899693 · NCT03223610
  • Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.
    Adv Hematol · 2024 · PMID 39563886 · NCT01855750
  • Daratumumab as a novel treatment option in refractory ITP.
    Blood Cells Mol Dis · 2023 · PMID 36669360 · NCT03129828

Bronchiolitis Obliterans Syndrome (33)

  • Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary.
    Ther Adv Hematol · 2026 · PMID 42180389 · NCT03112603
  • Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
    J Clin Oncol · 2025 · PMID 40561385 · NCT03112603
  • Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3.
    Blood Adv · 2025 · PMID 40472328 · NCT03112603
  • Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
    J Clin Oncol · 2023 · PMID 36608310 · NCT02959944
  • FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
    Oncologist · 2022 · PMID 35363318 · NCT03112603

Waldenstrom Macroglobulinemia (18)

  • Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.
    Blood · 2026 · PMID 41671559 · NCT02604511
  • Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.
    Blood Adv · 2025 · PMID 39626287 · NCT03053440
  • Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.
    Blood Adv · 2025 · PMID 40924923 · NCT03053440
  • Dose optimisation to improve access to effective cancer medicines.
    Lancet Oncol · 2025 · PMID 40049207 · NCT07474961
  • Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.
    Adv Ther · 2024 · PMID 38079089 · NCT04042376

Multiple Myeloma (18)

  • Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
    Cell Cycle · 2016 · PMID 25565020 · NCT03702725
  • Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.
    Cancer Res · 2015 · PMID 25589346 · NCT03702725
  • BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
    Cell Signal · 2013 · PMID 22975686 · NCT03702725
  • Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
    Blood · 2013 · PMID 23940282 · NCT03702725
  • Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
    Am J Hematol · 2013 · PMID 23456977 · NCT03702725

Publications by journal

Trial-results highlights

For patients with chronic lymphocytic leukemia (CLL), several trials investigated Ibrutinib. In NCT01578707, the median Progression Free Survival (PFS) by Independent Review Committee was NA months in the Ibrutinib arm, compared to 8.1 months in the Ofatumumab arm. In NCT01611090, the Ibrutinib+BR arm reported a median PFS of 65.12 Months, while the Placebo+BR arm reported 14.32 Months. Another study, NCT01722487, found the median PFS was 18.9 Months in the Chlorambucil arm, and NA Months in the Ibrutinib arm. In NCT01724346, with a median overall follow-up of 82.7 months, the median PFS based on investigator assessment was 106.9 months in the Ibrutinib arm, versus 15.0 months in the Chlorambucil arm.

In studies for Mantle Cell Lymphoma (MCL), Ibrutinib was also evaluated. In NCT01646021, the median PFS was 15.6 Months in the Ibrutinib arm and 6.2 Months in the Temsirolimus arm. In NCT01776840, the Ibrutinib + Bendamustine and Rituximab (BR) arm reported a median PFS of 80.6 months, while the Placebo + Bendamustine and Rituximab (BR) arm reported 52.9 months.

For Diffuse Large B-Cell Lymphoma (DLBCL), NCT01855750 investigated Ibrutinib in combination with R-CHOP. In the Activated B-Cell (ABC) population, the median Event-Free Survival (EFS) was 48.56 Months in the Ibrutinib+R-CHOP arm and 48.16 Months in the Placebo+R-CHOP arm. For the Intent-to-Treat (ITT) population, the median EFS was 49.64 Months in the Ibrutinib+R-CHOP arm and 54.77 Months in the Placebo+R-CHOP arm. All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.

All Ibrutinib publications (426)

2026 (14 papers)

  1. Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM).
    Yosipovitch G, Mosnaim G, Ortmann CE, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
    PubMed: PMID 41854973 · NCT06868212 (RECLAIM) · Chronic Urticaria
  2. Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Woyach JA, Qiu L, Grosicki S, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41353787 · NCT05254743 (BRUIN-CLL-314) · Leukemia, Lymphocytic, Chronic, B-Cell
  3. Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.
    Wang T, Yan Y, Wang H, et al. · EClinicalMedicine · 2026 · Derived
    PubMed: PMID 41497516 · NCT03980002 (BDHCLL001) · Leukemia, Lymphocytic, Chronic, B-Cell
  4. Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial.
    Tam CS, Shadman M, Ong SY, et al. · Curr Med Res Opin · 2026 · Derived
    PubMed: PMID 41686056 · NCT03734016 (ALPINE) · Leukemia, Lymphocytic, Chronic, B-Cell
  5. Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.
    Sun H, Sklavenitis-Pistofidis R, Liu S, et al. · Blood · 2026 · Derived
    PubMed: PMID 41671559 · NCT02604511 · Waldenstrom Macroglobulinemia
  6. Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary.
    Mahmoudjafari Z, Bhatt V, Xue Z, et al. · Ther Adv Hematol · 2026 · Derived
    PubMed: PMID 42180389 · NCT03112603 · Bronchiolitis Obliterans Syndrome
  7. Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.
    Handunnetti SM, Khot A, Blombery P, et al. · Blood Adv · 2026 · Derived
    PubMed: PMID 41380113 · NCT02471391 (AIM) · Lymphoma, Mantle-Cell
  8. Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.
    Fürstenau M, Niemann CU, Robrecht S, et al. · Blood · 2026 · Derived
    PubMed: PMID 41911073 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  9. Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Eyre TA, Hess LM, Masoudi E, et al. · Cancers (Basel) · 2026 · Derived
    PubMed: PMID 41749915 · NCT05254743 (BRUIN-CLL-314) · Leukemia, Lymphocytic, Chronic, B-Cell
  10. Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
    Dreyling M, Doorduijn J, Giné E, et al. · Lancet · 2026 · Derived
    PubMed: PMID 42134356 · NCT02858258 · Lymphoma, Mantle-Cell
  11. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.
    Davis KL, Yao CC, Zimmerman JAO, et al. · J Natl Compr Canc Netw · 2026 · Derived
    PubMed: PMID 41671463 · NCT02997761 · Burkitt Lymphoma
  12. Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas.
    Chavez JC, Napier E, Bondanza A, et al. · Blood Neoplasia · 2026 · Derived
    PubMed: PMID 41536778 · NCT03876028 · Lymphoma, Large B-Cell, Diffuse
  13. Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576.
    Castro JE, Lengerke-Diaz PA, Velez Lujan J, et al. · Adv Hematol · 2026 · Derived
    PubMed: PMID 35103064 · NCT02315768 · Leukemia, Lymphocytic, Chronic, B-Cell
  14. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
    Al-Sawaf O, Stumpf J, Zhang C, et al. · N Engl J Med · 2026 · Derived
    PubMed: PMID 41358601 · NCT04608318 (CLL17) · Leukemia, B-Cell

2025 (24 papers)

  1. Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.
    Langerbeins P, Robrecht S, Nieper P, et al. · J Clin Oncol · 2025 · Trial result
    PubMed: PMID 39602678 · NCT02863718 (CLL12) · Leukemia, Lymphocytic, Chronic, B-Cell
  2. Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
    Zeiser R, Russo D, Ram R, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40561385 · NCT03112603 · Bronchiolitis Obliterans Syndrome
  3. Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma.
    Yao Y, Yan Y, Suman VJ, et al. · Front Immunol · 2025 · Derived
    PubMed: PMID 39967670 · NCT03021460 · Melanoma
  4. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Wang M, Jurczak W, Trneny M, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 39914418 · NCT03112174 (SYMPATICO) · Lymphoma, Mantle-Cell
  5. First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients.
    Silkenstedt E, Dreyling M · Hematol Oncol · 2025 · Derived
    PubMed: PMID 40517546 · NCT06482684 (CARMAN) · Lymphoma, Mantle-Cell
  6. Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma.
    Sharp J, Shana'ah AY, Voorhees TJ, et al. · J Natl Compr Canc Netw · 2025 · Derived
    PubMed: PMID 40550489 · NCT03697512 (MALIBU) · Lymphoma, B-Cell, Marginal Zone
  7. Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma.
    Schaff LR, Piotrowski AF, Pentsova E, et al. · Neuro Oncol · 2025 · Derived
    PubMed: PMID 40269592 · NCT03703167 · Recurrence
  8. Hypertension in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in ALPINE: a secondary analysis.
    Rhee JW, Lamanna N, Aldairy W, et al. · Blood Neoplasia · 2025 · Derived
    PubMed: PMID 41424932 · NCT03734016 (ALPINE) · Leukemia, Lymphocytic, Chronic, B-Cell
  9. Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.
    Niemann CU, Dubois J, Nasserinejad K, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40249856 · NCT03226301
  10. Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3.
    Mahmoudjafari Z, Kintsch E, Xue Z, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40472328 · NCT03112603 · Bronchiolitis Obliterans Syndrome
  11. Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.
    Kater AP, Kersting S, Dubois JM, et al. · Lancet Haematol · 2025 · Derived
    PubMed: PMID 41338862 · NCT04639362
  12. Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.
    Heyman BM, Opat SS, Wahlin BE, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39626287 · NCT03053440 (ASPEN) · Waldenstrom Macroglobulinemia
  13. Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis.
    Guijosa A, Ramirez-Gamero A, Sarosiek S, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40674744 · NCT02165397 · Lymphoma
  14. Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.
    García-Sanz R, Owen RG, Jurczak W, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40924923 · NCT03053440 (ASPEN) · Waldenstrom Macroglobulinemia
  15. Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
    Dartigeas C, Quinquenel A, Ysebaert L, et al. · Ann Hematol · 2025 · Derived
    PubMed: PMID 38443660 · NCT03425591 (FIRE) · Leukemia, Lymphocytic, Chronic, B-Cell
  16. Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial.
    Condoluci A, Romano I, Dietrich D, et al. · Blood · 2025 · Derived
    PubMed: PMID 40009495 · NCT03708003 · Leukemia, Lymphocytic, Chronic, B-Cell
  17. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas.
    Chihara D, Steiner RE, Nair R, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39908461 · NCT03770416
  18. How well does acalabrutinib work and how safe is it to treat patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have had previous treatments? a plain language summary of 2 key studies.
    Byrd JC, Hakre S, Ghia P, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 40485230 · NCT02477696 · Leukemia, Lymphocytic, Chronic, B-Cell
  19. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.
    Burger JA, Barr PM, Robak T, et al. · Blood · 2025 · Derived
    PubMed: PMID 40737596 · NCT01724346 · Leukemia, Lymphocytic, Chronic, B-Cell
  20. Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study.
    Brown JR, Li J, Eichhorst BF, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39853273 · NCT03734016 (ALPINE) · Leukemia, Lymphocytic, Chronic, B-Cell
  21. Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
    Barr PM, Owen C, Robak T, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 36617990 · NCT01724346 · Leukemia, Lymphocytic, Chronic, B-Cell
  22. Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis.
    Alexandre J, Font J, Lenormand T, et al. · Exp Hematol Oncol · 2025 · Derived
    PubMed: PMID 40038806 · NCT06561243 · Cardiovascular Diseases
  23. Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials.
    Abuhelwa AY, Almansour SA, Brown JR, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40266025 · NCT01611090 · Leukemia, Lymphocytic, Chronic, B-Cell
  24. Dose optimisation to improve access to effective cancer medicines.
    Tannock IF, de Vries EGE, Fojo A, et al. · Lancet Oncol · 2025 · Background
    PubMed: PMID 40049207 · NCT07474961 (BLOOD-dose) · Waldenstrom Macroglobulinemia

2024 (29 papers)

  1. Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
    Stewart DA, Kuruvilla J, Lee D, et al. · Br J Haematol · 2024 · Trial result
    PubMed: PMID 38802107 · NCT02436707 · Lymphoma
  2. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Fürstenau M, Kater AP, Robrecht S, et al. · Lancet Oncol · 2024 · Trial result
    PubMed: PMID 38821083 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  3. Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
    Alcantara M, Chevrier M, Jardin F, et al. · J Hematol Oncol · 2024 · Trial result
    PubMed: PMID 39300447 · NCT04446962 (LOC-R01) · Lymphoma, Large B-Cell, Diffuse
  4. Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.
    Zhou K, Wang T, Pan L, et al. · Ann Hematol · 2024 · Derived
    PubMed: PMID 38888616 · NCT03734016 (ALPINE) · Leukemia, Lymphocytic, Chronic, B-Cell
  5. Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.
    Yi S, Cai Z, Hu Y, et al. · Adv Ther · 2024 · Derived
    PubMed: PMID 38079089 · NCT04042376 · Waldenstrom Macroglobulinemia
  6. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
    Woyach JA, Perez Burbano G, Ruppert AS, et al. · Blood · 2024 · Derived
    PubMed: PMID 38215395 · NCT01886872 · Leukemia, Lymphocytic, Chronic, B-Cell
  7. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
    Woyach JA, Jones D, Jurczak W, et al. · Blood · 2024 · Derived
    PubMed: PMID 38754046 · NCT02477696 · Leukemia, Lymphocytic, Chronic, B-Cell
  8. Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.
    Tedeschi A, Tam CS, Owen RG, et al. · Future Oncol · 2024 · Derived
    PubMed: PMID 39072392 · NCT03053440 (ASPEN) · Waldenstrom Macroglobulinemia
  9. Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial.
    Tam CS, Lamanna N, O'Brien SM, et al. · Curr Med Res Opin · 2024 · Derived
    PubMed: PMID 37752892 · NCT03734016 (ALPINE) · Leukemia, Lymphocytic, Chronic, B-Cell
  10. A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis.
    Shree T, Haebe S, Czerwinski DK, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 37939259 · NCT02927964 · Lymphoma, Mantle-Cell
  11. Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.
    Schwarz E, Benner B, Wesolowski R, et al. · JCI Insight · 2024 · Derived
    PubMed: PMID 39513363 · NCT03525925 · Neoplasm Metastasis
  12. Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112).
    Sancho JM, Abrisqueta P, Kumar A, et al. · Leuk Lymphoma · 2024 · Derived
    PubMed: PMID 38598516 · NCT03424122 · Lymphoma, Mantle-Cell
  13. Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial.
    O'Connell NS, Zhao F, Lee JW, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 37801678 · NCT02048813 · Leukemia, Lymphocytic, Chronic, B-Cell
  14. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
    Moslehi JJ, Furman RR, Tam CS, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 38502198 · NCT03734016 (ALPINE) · Leukemia, Lymphocytic, Chronic, B-Cell
  15. CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
    Minson A, Hamad N, Cheah CY, et al. · Blood · 2024 · Derived
    PubMed: PMID 37883795 · NCT04234061 (TARMAC) · Lymphoma, B-Cell
  16. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
    Melani C, Lakhotia R, Pittaluga S, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38899693 · NCT03223610 · Lymphoma, Large B-Cell, Diffuse
  17. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
    Langerbeins P, Giza A, Robrecht S, et al. · Blood · 2024 · Derived
    PubMed: PMID 38620092 · NCT02345863
  18. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
    Kater AP, Owen C, Moreno C, et al. · NEJM Evid · 2024 · Derived
    PubMed: PMID 38319255 · NCT03462719 (GLOW) · Leukemia, Lymphocytic, Chronic, B-Cell
  19. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
    Handunnetti SM, Anderson MA, Burbury K, et al. · Blood · 2024 · Derived
    PubMed: PMID 38662991 · NCT02471391 (AIM) · Lymphoma, Mantle-Cell
  20. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
    Gordon MJ, Feng L, Strati P, et al. · Cancer · 2024 · Derived
    PubMed: PMID 37985359 · NCT02532257 · Lymphoma, Follicular
  21. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
    Dreyling M, Doorduijn J, Giné E, et al. · Lancet · 2024 · Derived
    PubMed: PMID 38705160 · NCT02858258 · Lymphoma, Mantle-Cell
  22. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
    Dörner T, Kaul M, Szántó A, et al. · Ann Rheum Dis · 2024 · Derived
    PubMed: PMID 37932009 · NCT04035668 (LOUiSSe) · Immune System Diseases
  23. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
    Castillo JJ, Branagan AR, Sermer D, et al. · Blood · 2024 · Derived
    PubMed: PMID 37971194 · NCT04273139 · Waldenstrom Macroglobulinemia
  24. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.
    Brown JR, Eichhorst B, Lamanna N, et al. · Blood · 2024 · Derived
    PubMed: PMID 39316666 · NCT03734016 (ALPINE) · Leukemia, Lymphocytic, Chronic, B-Cell
  25. Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
    Brown JR, Eichhorst B, Hillmen P, et al. · Future Oncol · 2024 · Derived
    PubMed: PMID 38088119 · NCT03734016 (ALPINE) · Leukemia, Lymphocytic, Chronic, B-Cell
  26. Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.
    Alfaifi A, Bahashwan S, Alsaadi M, et al. · Adv Hematol · 2024 · Derived
    PubMed: PMID 39563886 · NCT01855750 · Lymphoma, Large B-Cell, Diffuse
  27. Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database.
    Alexandre J, Font J, Angélique DS, et al. · Leukemia · 2024 · Derived
    PubMed: PMID 39300222 · NCT06224452 · Hematologic Neoplasms
  28. Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
    Ahn IE, Brander DM, Ren Y, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 38163317 · NCT02251548 (iFCR) · Leukemia, Lymphocytic, Chronic, B-Cell
  29. Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial.
    Johnson TS, MacDonald TJ, Pacholczyk R, et al. · Neuro Oncol · 2024 · Background
    PubMed: PMID 37715730 · NCT05106296 · Brain Neoplasms

2023 (30 papers)

  1. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
    Eichhorst B, Niemann CU, Kater AP, et al. · N Engl J Med · 2023 · Trial result
    PubMed: PMID 37163621 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  2. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
    Westin J, Davis RE, Feng L, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 35952327 · NCT02636322
  3. Daratumumab as a novel treatment option in refractory ITP.
    Vernava I, Schmitt CA · Blood Cells Mol Dis · 2023 · Derived
    PubMed: PMID 36669360 · NCT03129828 (ImbruVeRCHOP) · Lymphoma, Large B-Cell, Diffuse
  4. Long-term Use of Ibrutinib in Japanese Patients with Steroid Dependent/Refractory cGVHD: Final Analysis of Multicenter Study.
    Toyosaki M, Doki N, Shiratori S, et al. · Blood Cell Ther · 2023 · Derived
    PubMed: PMID 38149026 · NCT03474679 · Graft vs Host Disease
  5. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Torka P, Thiruvengadam SK, Chen L, et al. · Blood Cancer J · 2023 · Derived
    PubMed: PMID 36631449 · NCT03479268 · Leukemia, Lymphocytic, Chronic, B-Cell
  6. Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.
    Sinha M, Betts C, Zhang L, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 36593070 · NCT02562898
  7. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
    Siddiqi T, Maloney DG, Kenderian SS, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37295445 · NCT03331198 · Leukemia, Lymphocytic, Chronic, B-Cell
  8. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
    Seymour JF, Byrd JC, Ghia P, et al. · Blood · 2023 · Derived
    PubMed: PMID 37390310 · NCT02477696 · Leukemia, Lymphocytic, Chronic, B-Cell
  9. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
    Rutherford SC, Yin J, Pederson L, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 35787017 · NCT01829568
  10. The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
    Ramchandren R, Johnson P, Ghosh N, et al. · EClinicalMedicine · 2023 · Derived
    PubMed: PMID 36618900 · NCT02077166 · Lymphoma, Large B-Cell, Diffuse
  11. Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
    Oh DY, Maqueda MA, Quinn DI, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 37919668 · NCT02599324 · Carcinoma, Renal Cell
  12. Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
    Novak U, Fehr M, Schär S, et al. · EClinicalMedicine · 2023 · Derived
    PubMed: PMID 37781158 · NCT02356458 · Lymphoma, Mantle-Cell
  13. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Niemann CU, Munir T, Moreno C, et al. · Lancet Oncol · 2023 · Derived
    PubMed: PMID 37944541 · NCT03462719 (GLOW) · Leukemia, Lymphocytic, Chronic, B-Cell
  14. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
    Nastoupil LJ, Hess G, Pavlovsky MA, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 37722354 · NCT01974440 (SELENE) · Lymphoma
  15. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.
    Moreno C, Solman IG, Tam CS, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 37315225 · NCT02910583 (Captivate) · Leukemia, Lymphocytic, Chronic, B-Cell
  16. Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.
    Miklos DB, Abu Zaid M, Cooney JP, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36608310 · NCT02959944 (iNTEGRATE) · Bronchiolitis Obliterans Syndrome
  17. A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
    Michallet AS, Letestu R, Le Garff-Tavernier M, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 37026799 · NCT02666898 (ICLL07GAI) · Leukemia, Lymphocytic, Chronic, B-Cell
  18. Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.
    Karmali R, Abramson JS, Stephens DM, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 37756532 · NCT02242097 · Lymphoma, Mantle-Cell
  19. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial.
    Johnson PWM, Balasubramanian S, Hodkinson B, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 36696540 · NCT01855750 · Lymphoma, Large B-Cell, Diffuse
  20. PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.
    Jayappa KD, Tran B, Gordon VL, et al. · J Clin Invest · 2023 · Derived
    PubMed: PMID 37166997 · NCT02419560 · Lymphoma, Mantle-Cell
  21. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.
    Jain N, Senapati J, Thakral B, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 36287248 · NCT02420912 · Leukemia, Lymphocytic, Chronic, B-Cell
  22. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
    Fürstenau M, Thus YJ, Robrecht S, et al. · Blood · 2023 · Derived
    PubMed: PMID 37172204 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  23. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
    Eyre TA, Shah NN, Dreyling M, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 36377973 · NCT04662255 (BRUIN-MCL-321) · Lymphoma, Mantle-Cell
  24. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
    Dimopoulos MA, Opat S, D'Sa S, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37478390 · NCT03053440 (ASPEN) · Waldenstrom Macroglobulinemia
  25. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.
    Decombis S, Bellanger C, Le Bris Y, et al. · Blood · 2023 · Derived
    PubMed: PMID 37562004 · NCT02558816 (OAsIs) · Lymphoma, Mantle-Cell
  26. Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.
    Casulo C, Santoro A, Cartron G, et al. · Cancer Rep (Hoboken) · 2023 · Derived
    PubMed: PMID 35852004 · NCT02733042 (FUSION NHL 001) · Leukemia, Lymphocytic, Chronic, B-Cell
  27. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
    Buske C, Tedeschi A, Trotman J, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 36815271 · NCT02165397 · Lymphoma
  28. Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial.
    Burke GAA, Vinti L, Kabickova E, et al. · Blood Adv · 2023 · Derived
    PubMed: PMID 36541957 · NCT02703272 · Lymphoma, Non-Hodgkin
  29. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
    Hillmen P, Eichhorst B, Brown JR, et al. · J Clin Oncol · 2023 · Background
    PubMed: PMID 36395435 · NCT03734016 (ALPINE) · Leukemia, Lymphocytic, Chronic, B-Cell
  30. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Brown JR, Eichhorst B, Hillmen P, et al. · N Engl J Med · 2023 · Background
    PubMed: PMID 36511784 · NCT03734016 (ALPINE) · Leukemia, Lymphocytic, Chronic, B-Cell

2022 (33 papers)

  1. Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.
    Xu PP, Shi ZY, Qian Y, et al. · Lancet Healthy Longev · 2022 · Derived
    PubMed: PMID 36102758 · NCT03949062 · Lymphoma, Large B-Cell, Diffuse
  2. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.
    Wilson WH, Wright GW, Huang DW, et al. · Cancer Cell · 2022 · Derived
    PubMed: PMID 34739844 · NCT01855750 · Lymphoma, Large B-Cell, Diffuse
  3. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
    Wang ML, Jurczak W, Jerkeman M, et al. · N Engl J Med · 2022 · Derived
    PubMed: PMID 35657079 · NCT01776840 · Lymphoma, Mantle-Cell
  4. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
    Wang ML, Jain P, Zhao S, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35074072 · NCT02427620 · Lymphoma, Mantle-Cell
  5. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.
    Trotman J, Buske C, Tedeschi A, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34380643 · NCT02165397 · Lymphoma
  6. A phase two study of high dose blinatumomab in Richter's syndrome.
    Thompson PA, Jiang X, Banerjee P, et al. · Leukemia · 2022 · Derived
    PubMed: PMID 35941212 · NCT03121534 · Hematologic Neoplasms
  7. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications.
    Teoh J, Brown LF · Cytotherapy · 2022 · Derived
    PubMed: PMID 35610089 · NCT03331198 · Leukemia, Lymphocytic, Chronic, B-Cell
  8. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
    Stewart CM, Michaud L, Whiting K, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34615723 · NCT02756247 · Lymphoma, Mantle-Cell
  9. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
    Siddiqi T, Soumerai JD, Dorritie KA, et al. · Blood · 2022 · Derived
    PubMed: PMID 34699592 · NCT03331198 · Leukemia, Lymphocytic, Chronic, B-Cell
  10. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
    Shanafelt TD, Wang XV, Hanson CA, et al. · Blood · 2022 · Derived
    PubMed: PMID 35427411 · NCT02048813 · Leukemia, Lymphocytic, Chronic, B-Cell
  11. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
    Portell CA, Wages NA, Kahl BS, et al. · Blood Adv · 2022 · Derived
    PubMed: PMID 34700344 · NCT02419560 · Lymphoma, Mantle-Cell
  12. Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response.
    Peragine N, De Propris MS, Intoppa S, et al. · Leuk Lymphoma · 2022 · Derived
    PubMed: PMID 35913400 · NCT02232386 (LLC1114)
  13. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
    Moreno C, Greil R, Demirkan F, et al. · Haematologica · 2022 · Derived
    PubMed: PMID 35021599 · NCT02264574 · Leukemia, Lymphocytic, Chronic, B-Cell
  14. Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy.
    Mooney KL, Czerwinski DK, Shree T, et al. · Cancer Cytopathol · 2022 · Derived
    PubMed: PMID 34780125 · NCT02927964 · Lymphoma, Mantle-Cell
  15. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
    Le RQ, Wang X, Zhang H, et al. · Oncologist · 2022 · Derived
    PubMed: PMID 35363318 · NCT03112603 · Bronchiolitis Obliterans Syndrome
  16. What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?
    Kumar A · Hematology Am Soc Hematol Educ Program · 2022 · Derived
    PubMed: PMID 36485104 · NCT02858258 · Lymphoma, Mantle-Cell
  17. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
    Kater AP, Levin MD, Dubois J, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35654052 · NCT03226301
  18. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
    Jain P, Zhao S, Lee HJ, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 34797699 · NCT02427620 · Lymphoma, Mantle-Cell
  19. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
    Jain N, Keating M, Thompson P, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 34110383 · NCT02756897 · Leukemia, Lymphocytic, Chronic, B-Cell
  20. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
    Giné E, de la Cruz F, Jiménez Ubieto A, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35030036 · NCT02682641 · Lymphoma, Mantle-Cell
  21. FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL.
    Dartigeas C, Slama B, Doyle M, et al. · Clin Hematol Int · 2022 · Derived
    PubMed: PMID 36103041 · NCT03425591 (FIRE) · Leukemia, Lymphocytic, Chronic, B-Cell
  22. Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study.
    Coutre SE, Barnett C, Osiyemi O, et al. · Open Forum Infect Dis · 2022 · Derived
    PubMed: PMID 35493119 · NCT04375397 (iNSPIRE) · COVID-19
  23. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
    Castillo JJ, Meid K, Gustine JN, et al. · Leukemia · 2022 · Derived
    PubMed: PMID 34531537 · NCT02604511 · Waldenstrom Macroglobulinemia
  24. BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.
    Butler M, van Ingen Schenau DS, Yu J, et al. · Blood · 2022 · Derived
    PubMed: PMID 34280258 · NCT02884453 (iMYC)
  25. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
    Buske C, Tedeschi A, Trotman J, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 34606378 · NCT02165397 · Lymphoma
  26. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
    Burger JA, Robak T, Demirkan F, et al. · Leuk Lymphoma · 2022 · Derived
    PubMed: PMID 35014928 · NCT01722487 · Leukemia, Lymphocytic, Chronic, B-Cell
  27. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
    Barr PM, Owen C, Robak T, et al. · Blood Adv · 2022 · Derived
    PubMed: PMID 35377947 · NCT01724346 · Leukemia, Lymphocytic, Chronic, B-Cell
  28. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
    Balasubramanian S, Hodkinson B, Schuster SJ, et al. · Cancer Med · 2022 · Derived
    PubMed: PMID 34791836 · NCT01779791 · Lymphoma
  29. Illness representations and psychological outcomes in chronic lymphocytic leukaemia.
    Arrato NA, Valentine TR, Byrd JC, et al. · Br J Health Psychol · 2022 · Derived
    PubMed: PMID 34608724 · NCT02518555 · Leukemia, Lymphocytic, Chronic, B-Cell
  30. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    Allan JN, Shanafelt T, Wiestner A, et al. · Br J Haematol · 2022 · Derived
    PubMed: PMID 34865212 · NCT02048813 · Leukemia, Lymphocytic, Chronic, B-Cell
  31. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
    Stephens DM, Huang Y, Ruppert AS, et al. · Clin Cancer Res · 2022 · Background
    PubMed: PMID 35608822 · NCT02303392 · Leukemia, Lymphocytic, Chronic, B-Cell
  32. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
    Langerbeins P, Zhang C, Robrecht S, et al. · Blood · 2022 · Background
    PubMed: PMID 34758069 · NCT02863718 (CLL12) · Leukemia, Lymphocytic, Chronic, B-Cell
  33. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
    Ferreri AJM, Cwynarski K, Pulczynski E, et al. · Leukemia · 2022 · Background
    PubMed: PMID 35562406 · NCT05782374 (ReWIPretro)

2021 (40 papers)

  1. Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation-A Potentially Beneficial Drug-Drug Interaction.
    Tapaninen T, Olkkola AM, Tornio A, et al. · Clin Transl Sci · 2021 · Trial result
    PubMed: PMID 31664782 · NCT05348096 · Bronchiolitis Obliterans Syndrome
  2. CURATE.AI: Optimizing Personalized Medicine with Artificial Intelligence.
    Blasiak A, Khong J, Kee T, et al. · SLAS Technol · 2021 · Trial result
    PubMed: PMID 31771394 · NCT04522284 · Waldenstrom Macroglobulinemia
  3. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
    Zeiser R, Polverelli N, Ram R, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 34260836 · NCT03112603 · Bronchiolitis Obliterans Syndrome
  4. Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
    Xia M, Luo TY, Shi Y, et al. · J Immunol · 2021 · Derived
    PubMed: PMID 33067379 · NCT02912754 · Leukemia, Lymphocytic, Chronic, B-Cell
  5. Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Wilson WH, Phillips T, Popplewell L, et al. · Leuk Lymphoma · 2021 · Derived
    PubMed: PMID 33856277 · NCT02142049 · Lymphoma
  6. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    Wierda WG, Allan JN, Siddiqi T, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34618601 · NCT02910583 (Captivate) · Leukemia, Lymphocytic, Chronic, B-Cell
  7. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
    Wang M, Ramchandren R, Chen R, et al. · J Hematol Oncol · 2021 · Derived
    PubMed: PMID 34717692 · NCT03112174 (SYMPATICO) · Lymphoma, Mantle-Cell
  8. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
    Treon SP, Meid K, Hunter ZR, et al. · Blood · 2021 · Derived
    PubMed: PMID 34289017 · NCT03225716 · Waldenstrom Macroglobulinemia
  9. Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial.
    Tan BKJ, Teo CB, Tadeo X, et al. · Front Digit Health · 2021 · Derived
    PubMed: PMID 34713106 · NCT04522284 · Waldenstrom Macroglobulinemia
  10. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP, Brander DM, Mato AR, et al. · Lancet Haematol · 2021 · Derived
    PubMed: PMID 33631112 · NCT02301156 (GENUINE) · Leukemia, Lymphocytic, Chronic, B-Cell
  11. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
    Ruppert AS, Booth AM, Ding W, et al. · Leukemia · 2021 · Derived
    PubMed: PMID 34274940 · NCT01886872 · Leukemia, Lymphocytic, Chronic, B-Cell
  12. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Rogers KA, Huang Y, Ruppert AS, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32795224 · NCT02427451 · Leukemia, Lymphocytic, Chronic, B-Cell
  13. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
    Rogers KA, Andritsos LA, Wei L, et al. · Blood · 2021 · Derived
    PubMed: PMID 33754642 · NCT01841723 · Leukemia, Hairy Cell
  14. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
    Noy A, de Vos S, Coleman M, et al. · Blood Adv · 2021 · Derived
    PubMed: PMID 33227125 · NCT01980628 · Lymphoma, B-Cell
  15. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
    Moschos SJ, Eroglu Z, Khushalani NI, et al. · Melanoma Res · 2021 · Derived
    PubMed: PMID 33661190 · NCT02581930 · Melanoma
  16. A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
    Michallet AS, Letestu R, Le Garff-Tavernier M, et al. · Blood · 2021 · Derived
    PubMed: PMID 33167024 · NCT02666898 (ICLL07GAI) · Leukemia, Lymphocytic, Chronic, B-Cell
  17. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.
    List AF, Sun Z, Verma A, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33439748 · NCT02048813 · Leukemia, Lymphocytic, Chronic, B-Cell
  18. Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.
    Levin MD, Kater AP, Mattsson M, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 33060089 · NCT03226301
  19. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
    Le Gouill S, Morschhauser F, Chiron D, et al. · Blood · 2021 · Derived
    PubMed: PMID 33181832 · NCT02558816 (OAsIs) · Lymphoma, Mantle-Cell
  20. Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies.
    Krebs S, Mauguen A, Yildirim O, et al. · Eur J Nucl Med Mol Imaging · 2021 · Derived
    PubMed: PMID 33966087 · NCT02315326 · Recurrence
  21. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia.
    Kipps TJ · Cancer J · 2021 · Derived
    PubMed: PMID 34398557 · NCT03088878 · Leukemia, Lymphocytic, Chronic, B-Cell
  22. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
    Kim DW, Tan E, Zhou JM, et al. · Br J Cancer · 2021 · Derived
    PubMed: PMID 33828254 · NCT03332498 · Colonic Diseases
  23. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
    Greil R, Tedeschi A, Moreno C, et al. · Ann Hematol · 2021 · Derived
    PubMed: PMID 34018029 · NCT02264574 · Leukemia, Lymphocytic, Chronic, B-Cell
  24. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Fraser GAM, Chanan-Khan A, Demirkan F, et al. · Leuk Lymphoma · 2021 · Derived
    PubMed: PMID 32762271 · NCT01611090 · Leukemia, Lymphocytic, Chronic, B-Cell
  25. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M, Oeser A, Besiroglu B, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34515338 · NCT03310619 (PLATFORM) · Lymphoma, Large B-Cell, Diffuse
  26. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Doki N, Toyosaki M, Shiratori S, et al. · Transplant Cell Ther · 2021 · Derived
    PubMed: PMID 34102349 · NCT03474679 · Graft vs Host Disease
  27. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
    de Jong J, Mitselos A, Jurczak W, et al. · Pharmacol Res Perspect · 2021 · Derived
    PubMed: PMID 32945596 · NCT03301207 · Leukemia, Lymphocytic, Chronic, B-Cell
  28. Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.
    Davis JE, Handunnetti SM, Ludford-Menting M, et al. · Blood Adv · 2021 · Derived
    PubMed: PMID 33031542 · NCT02471391 (AIM) · Lymphoma, Mantle-Cell
  29. Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
    Cramer P, Tresckow JV, Robrecht S, et al. · Haematologica · 2021 · Derived
    PubMed: PMID 32107341 · NCT02689141 · Leukemia, Lymphocytic, Chronic, B-Cell
  30. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Cramer P, Tausch E, von Tresckow J, et al. · Blood · 2021 · Derived
    PubMed: PMID 34086865 · NCT02689141 · Leukemia, Lymphocytic, Chronic, B-Cell
  31. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.
    Chu Y, Lee S, Shah T, et al. · Oncoimmunology · 2021 · Derived
    PubMed: PMID 30546948 · NCT02703272 · Lymphoma, Non-Hodgkin
  32. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
    Byrd JC, Hillmen P, Ghia P, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34310172 · NCT02477696 · Leukemia, Lymphocytic, Chronic, B-Cell
  33. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.
    Bruscaggin A, di Bergamo LT, Spina V, et al. · Blood Adv · 2021 · Derived
    PubMed: PMID 34500472 · NCT02329847 · Hematologic Neoplasms
  34. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.
    Wolff D, Fatobene G, Rocha V, et al. · Bone Marrow Transplant · 2021 · Background
    PubMed: PMID 34218265 · NCT05348096 · Bronchiolitis Obliterans Syndrome
  35. Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX-based regimens in clinical routine.
    Sieg N, Naendrup JH, Gödel P, et al. · Eur J Haematol · 2021 · Background
    PubMed: PMID 33960535 · NCT05782374 (ReWIPretro)
  36. Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity.
    Sharma MD, Pacholczyk R, Shi H, et al. · Immunity · 2021 · Background
    PubMed: PMID 34614413 · NCT05106296 · Brain Neoplasms
  37. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
    Schorb E, Fox CP, Kasenda B, et al. · Br J Haematol · 2021 · Background
    PubMed: PMID 31997308 · NCT05782374 (ReWIPretro)
  38. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
    Louis DN, Perry A, Wesseling P, et al. · Neuro Oncol · 2021 · Background
    PubMed: PMID 34185076 · NCT05782374 (ReWIPretro)
  39. Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
    Kaji FA, Martinez-Calle N, Bishton MJ, et al. · Br J Haematol · 2021 · Background
    PubMed: PMID 34368948 · NCT05782374 (ReWIPretro)
  40. Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702-2705.
    Blood · 2021 · Background
    PubMed: PMID 28705863 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell

2020 (15 papers)

  1. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
    Waller EK, Miklos D, Cutler C, et al. · Biol Blood Marrow Transplant · 2020 · Trial result
    PubMed: PMID 31260802 · NCT05348096 · Bronchiolitis Obliterans Syndrome
  2. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    Moreno C, Greil R, Demirkan F, et al. · Lancet Oncol · 2020 · Trial result
    PubMed: PMID 30522969 · NCT02264574 · Leukemia, Lymphocytic, Chronic, B-Cell
  3. Artificial intelligence in cancer therapy.
    Ho D · Science · 2020 · Trial result
    PubMed: PMID 32108102 · NCT04522284 · Waldenstrom Macroglobulinemia
  4. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P, Brown JR, Eichhorst BF, et al. · Future Oncol · 2020 · Trial result
    PubMed: PMID 32207333 · NCT03734016 (ALPINE) · Leukemia, Lymphocytic, Chronic, B-Cell
  5. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
    Younes A, Sehn LH, Johnson P, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 30901302 · NCT01855750 · Lymphoma, Large B-Cell, Diffuse
  6. Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
    Spaner DE, McCaw L, Wang G, et al. · Cancer Med · 2020 · Derived
    PubMed: PMID 30843659 · NCT02912754 · Leukemia, Lymphocytic, Chronic, B-Cell
  7. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
    Soussain C, Choquet S, Blonski M, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 31279304 · NCT02542514 (iLOC) · Intraocular Lymphoma
  8. Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
    Muqbil I, Chaker M, Aboukameel A, et al. · Heliyon · 2020 · Derived
    PubMed: PMID 31508518 · NCT02824029 · Hodgkin Disease
  9. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T, Brown JR, O'Brien S, et al. · Am J Hematol · 2020 · Derived
    PubMed: PMID 31512258 · NCT01578707 (RESONATE™) · Leukemia, Lymphocytic, Chronic, B-Cell
  10. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Lunning M, Vose J, Nastoupil L, et al. · Blood · 2020 · Derived
    PubMed: PMID 31558467 · NCT02006485 · Leukemia, Lymphocytic, Chronic, B-Cell
  11. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
    Goy A, Ramchandren R, Ghosh N, et al. · Blood · 2020 · Derived
    PubMed: PMID 31331917 · NCT02077166 · Lymphoma, Large B-Cell, Diffuse
  12. COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
    Fürstenau M, Langerbeins P, De Silva N, et al. · Leukemia · 2020 · Derived
    PubMed: PMID 32601378 · NCT02950051 (GAIA) · Leukemia, Lymphocytic, Chronic, B-Cell
  13. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Coutre SE, Byrd JC, Hillmen P, et al. · Blood Adv · 2020 · Derived
    PubMed: PMID 31196847 · NCT01578707 (RESONATE™) · Leukemia, Lymphocytic, Chronic, B-Cell
  14. [Ibrutinib treatment for 2 cases of relapsed/refractory autoimmune hemolytic anemia: a pilot study].
    Fang LW, Pan H, Shi J, et al. · Zhonghua Xue Ye Xue Za Zhi · 2020 · Background
    PubMed: PMID 32536139 · NCT04398459 · Anemia, Hemolytic, Autoimmune
  15. A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response.
    Denker S, Bittner A, Na IK, et al. · Int J Hematol Oncol · 2020 · Background
    PubMed: PMID 31903182 · NCT03129828 (ImbruVeRCHOP) · Lymphoma, Large B-Cell, Diffuse

2019 (32 papers)

  1. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
    von Tresckow J, Cramer P, Bahlo J, et al. · Leukemia · 2019 · Trial result
    PubMed: PMID 30568174 · NCT02345863
  2. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
    Rashid MBMA, Toh TB, Hooi L, et al. · Sci Transl Med · 2019 · Trial result
    PubMed: PMID 30089632 · NCT04522284 · Waldenstrom Macroglobulinemia
  3. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A, Brody J, Carpio C, et al. · Lancet Haematol · 2019 · Derived
    PubMed: PMID 30642819 · NCT02329847 · Hematologic Neoplasms
  4. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
    Woyach JA, Ruppert AS, Heerema NA, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 30501481 · NCT01886872 · Leukemia, Lymphocytic, Chronic, B-Cell
  5. A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
    Ujjani C, Wang H, Skarbnik A, et al. · Blood Adv · 2019 · Derived
    PubMed: PMID 29610115 · NCT02200848 · Leukemia, Lymphocytic, Chronic, B-Cell
  6. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
    Treon SP, Gustine J, Meid K, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 30044692 · NCT02604511 · Waldenstrom Macroglobulinemia
  7. Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
    Shi Y, Wang G, Muhowski EM, et al. · Leukemia · 2019 · Derived
    PubMed: PMID 30696950 · NCT02912754 · Leukemia, Lymphocytic, Chronic, B-Cell
  8. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
    Shanafelt TD, Wang XV, Kay NE, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31365801 · NCT02048813 · Leukemia, Lymphocytic, Chronic, B-Cell
  9. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
    Sauter CS, Matasar MJ, Schoder H, et al. · Blood · 2019 · Derived
    PubMed: PMID 29386196 · NCT02219737 · Lymphoma, Large B-Cell, Diffuse
  10. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
    Rogers KA, Huang Y, Ruppert AS, et al. · Blood · 2019 · Derived
    PubMed: PMID 30111609 · NCT02427451 · Leukemia, Lymphocytic, Chronic, B-Cell
  11. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    O'Brien SM, Jaglowski S, Byrd JC, et al. · JAMA Oncol · 2019 · Derived
    PubMed: PMID 29470582 · NCT01578707 (RESONATE™) · Leukemia, Lymphocytic, Chronic, B-Cell
  12. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
    Nastoupil LJ, Lunning MA, Vose JM, et al. · Lancet Haematol · 2019 · Derived
    PubMed: PMID 30709431 · NCT02006485 · Leukemia, Lymphocytic, Chronic, B-Cell
  13. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
    Michallet AS, Dilhuydy MS, Subtil F, et al. · Lancet Haematol · 2019 · Derived
    PubMed: PMID 31324600 · NCT02666898 (ICLL07GAI) · Leukemia, Lymphocytic, Chronic, B-Cell
  14. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Martin P, Bartlett NL, Blum KA, et al. · Blood · 2019 · Derived
    PubMed: PMID 30692121 · NCT02159755 · Lymphoma, Mantle-Cell
  15. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
    Lavezzi SM, de Jong J, Neyens M, et al. · Pharm Res · 2019 · Derived
    PubMed: PMID 31044267 · NCT01611090 · Leukemia, Lymphocytic, Chronic, B-Cell
  16. Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.
    Kumar A, Vardhana S, Moskowitz AJ, et al. · Blood Adv · 2019 · Derived
    PubMed: PMID 29669753 · NCT02309580 · Recurrence
  17. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
    Jain P, Romaguera J, Srour SA, et al. · Br J Haematol · 2019 · Derived
    PubMed: PMID 29785709 · NCT02427620 · Lymphoma, Mantle-Cell
  18. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    Jain N, Keating M, Thompson P, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31141631 · NCT02756897 · Leukemia, Lymphocytic, Chronic, B-Cell
  19. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trials.
    Jagasia M, Zeiser R, Arbushites M, et al. · Immunotherapy · 2019 · Derived
    PubMed: PMID 29316837 · NCT03112603 · Bronchiolitis Obliterans Syndrome
  20. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Grommes C, Tang SS, Wolfe J, et al. · Blood · 2019 · Derived
    PubMed: PMID 30567753 · NCT02315326 · Recurrence
  21. Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
    Gopal AK, Schuster SJ, Fowler NH, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29851546 · NCT01779791 · Lymphoma
  22. Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy.
    Dispenza MC, Pongracic JA, Singh AM, et al. · J Allergy Clin Immunol · 2019 · Derived
    PubMed: PMID 29360526 · NCT03149315 · Food Hypersensitivity
  23. The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure.
    de Jong J, Haddish-Berhane N, Hellemans P, et al. · Cancer Chemother Pharmacol · 2019 · Derived
    PubMed: PMID 29882017 · NCT02638116
  24. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS, Kim HT, Nicotra A, et al. · Lancet Haematol · 2019 · Derived
    PubMed: PMID 30558987 · NCT02268851 · Leukemia, Lymphocytic, Chronic, B-Cell
  25. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
    Davids MS, Brander DM, Kim HT, et al. · Lancet Haematol · 2019 · Derived
    PubMed: PMID 31208944 · NCT02251548 (iFCR) · Leukemia, Lymphocytic, Chronic, B-Cell
  26. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
    Chen LS, Bose P, Cruz ND, et al. · Blood · 2019 · Derived
    PubMed: PMID 30254130 · NCT02801578 · Leukemia, Lymphocytic, Chronic, B-Cell
  27. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
    Byrd JC, Hillmen P, O'Brien S, et al. · Blood · 2019 · Derived
    PubMed: PMID 30842083 · NCT01578707 (RESONATE™) · Leukemia, Lymphocytic, Chronic, B-Cell
  28. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
    Burger JA, Sivina M, Jain N, et al. · Blood · 2019 · Derived
    PubMed: PMID 30530801 · NCT02007044 · Leukemia, Lymphocytic, Chronic, B-Cell
  29. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
    Bartlett NL, Costello BA, LaPlant BR, et al. · Blood · 2019 · Derived
    PubMed: PMID 29074501 · NCT01849263 · Lymphoma, Follicular
  30. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM, Robak T, Owen C, et al. · Haematologica · 2019 · Derived
    PubMed: PMID 29880603 · NCT01724346 · Leukemia, Lymphocytic, Chronic, B-Cell
  31. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
    Hallek M, Cheson BD, Catovsky D, et al. · Blood · 2019 · Background
    PubMed: PMID 29540348 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  32. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
    Cramer P, von Tresckow J, Bahlo J, et al. · Lancet Oncol · 2019 · Background
    PubMed: PMID 30115596 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell

2018 (11 papers)

  1. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS, LeBlond V, Novotny W, et al. · Future Oncol · 2018 · Trial result
    PubMed: PMID 29869556 · NCT03053440 (ASPEN) · Waldenstrom Macroglobulinemia
  2. Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.
    Spaner DE, Wang G, McCaw L, et al. · Haematologica · 2018 · Trial result
    PubMed: PMID 26819050 · NCT02912754 · Leukemia, Lymphocytic, Chronic, B-Cell
  3. Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.
    Oppermann S, Lam AJ, Tung S, et al. · Oncotarget · 2018 · Trial result
    PubMed: PMID 27579615 · NCT02912754 · Leukemia, Lymphocytic, Chronic, B-Cell
  4. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    Tam CS, Anderson MA, Pott C, et al. · N Engl J Med · 2018 · Derived
    PubMed: PMID 29590547 · NCT02471391 (AIM) · Lymphoma, Mantle-Cell
  5. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
    Jerkeman M, Eskelund CW, Hutchings M, et al. · Lancet Haematol · 2018 · Derived
    PubMed: PMID 29396091 · NCT02460276 (PHILEMON) · Lymphoma, Mantle-Cell
  6. Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.
    Chong IY, Aronson L, Bryant H, et al. · Gut · 2018 · Derived
    PubMed: PMID 28830912 · NCT02884453 (iMYC)
  7. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
    Brown JR, Moslehi J, O'Brien S, et al. · Haematologica · 2018 · Derived
    PubMed: PMID 28751558 · NCT01722487 · Leukemia, Lymphocytic, Chronic, B-Cell
  8. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Vitale C, Ahn IE, Sivina M, et al. · Haematologica · 2018 · Background
    PubMed: PMID 27013651 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  9. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Seymour JF, Kipps TJ, Eichhorst B, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29562156 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  10. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C, Pastore A, Palaskas N, et al. · Cancer Discov · 2018 · Background
    PubMed: PMID 28619981 · NCT04066920
  11. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
    Dimopoulos MA, Tedeschi A, Trotman J, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29856685 · NCT02165397 · Lymphoma

2017 (12 papers)

  1. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
    Ujjani CS, Jung SH, Pitcher B, et al. · Blood · 2017 · Derived
    PubMed: PMID 27697771 · NCT01829568
  2. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
    O'Brien S, Jones JA, Coutre SE, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27637985 · NCT01744691
  3. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
    Noy A, de Vos S, Thieblemont C, et al. · Blood · 2017 · Derived
    PubMed: PMID 28167659 · NCT01980628 · Lymphoma, B-Cell
  4. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
    Miklos D, Cutler CS, Arora M, et al. · Blood · 2017 · Derived
    PubMed: PMID 28924018 · NCT02195869 · Bronchiolitis Obliterans Syndrome
  5. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
    Maruyama D, Nagai H, Fukuhara N, et al. · Cancer Sci · 2017 · Derived
    PubMed: PMID 27616553 · NCT02169180 · Lymphoma, Mantle-Cell
  6. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M, Beckwith K, Do P, et al. · J Clin Invest · 2017 · Derived
    PubMed: PMID 28714866 · NCT01589302 · Leukemia, Lymphocytic, Chronic, B-Cell
  7. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
    Ding W, LaPlant BR, Call TG, et al. · Blood · 2017 · Derived
    PubMed: PMID 28424162 · NCT02332980 · Leukemia, Lymphocytic, Chronic, B-Cell
  8. Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.
    de Jong J, Hellemans P, Jiao JJ, et al. · Cancer Chemother Pharmacol · 2017 · Derived
    PubMed: PMID 29080970 · NCT02271438
  9. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
    Barr PM, Brown JR, Hillmen P, et al. · Blood · 2017 · Derived
    PubMed: PMID 28373262 · NCT01578707 (RESONATE™) · Leukemia, Lymphocytic, Chronic, B-Cell
  10. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.
    Ahn IE, Jerussi T, Farooqui M, et al. · Blood · 2017 · Derived
    PubMed: PMID 27503501 · NCT02514083 · Leukemia, Lymphocytic, Chronic, B-Cell
  11. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
    Lionakis MS, Dunleavy K, Roschewski M, et al. · Cancer Cell · 2017 · Background
    PubMed: PMID 28552327 · NCT04066920
  12. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
    Dimopoulos MA, Trotman J, Tedeschi A, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27956157 · NCT02165397 · Lymphoma

2016 (16 papers)

  1. Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform.
    Zarrinpar A, Lee DK, Silva A, et al. · Sci Transl Med · 2016 · Trial result
    PubMed: PMID 27053773 · NCT04522284 · Waldenstrom Macroglobulinemia
  2. Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial.
    Wilken R, Li CS, Sharon VR, et al. · Trials · 2016 · Derived
    PubMed: PMID 26297574 · NCT02351037 · Leukemia, Myeloid, Acute
  3. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
    Wang ML, Lee H, Chuang H, et al. · Lancet Oncol · 2016 · Derived
    PubMed: PMID 26640039 · NCT01880567 · Lymphoma, Mantle-Cell
  4. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ, Ruppert AS, Lozanski G, et al. · JAMA Oncol · 2016 · Derived
    PubMed: PMID 26182309 · NCT01578707 (RESONATE™) · Leukemia, Lymphocytic, Chronic, B-Cell
  5. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Dreyling M, Jurczak W, Jerkeman M, et al. · Lancet · 2016 · Derived
    PubMed: PMID 26673811 · NCT01646021 · Lymphoma, Mantle-Cell
  6. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A, Cramer P, Demirkan F, et al. · Lancet Oncol · 2016 · Derived
    PubMed: PMID 26655421 · NCT01611090 · Leukemia, Lymphocytic, Chronic, B-Cell
  7. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    Burger JA, Tedeschi A, Barr PM, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 26639149 · NCT01722487 · Leukemia, Lymphocytic, Chronic, B-Cell
  8. Safe utilization of ibrutinib with or without steroids in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia.
    St Bernard R, Hsia CC · Ann Hematol · 2016 · Background
    PubMed: PMID 26334319 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  9. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
    Schutt SD, Fu J, Nguyen H, et al. · PLoS One · 2016 · Background
    PubMed: PMID 26348529 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  10. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.
    Rogers KA, Ruppert AS, Bingman A, et al. · Leukemia · 2016 · Background
    PubMed: PMID 26442611 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  11. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Roberts AW, Davids MS, Pagel JM, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 26639348 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  12. Chronic lymphocytic leukemia (CLL)-Then and now.
    Rai KR, Jain P · Am J Hematol · 2016 · Background
    PubMed: PMID 26690614 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  13. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
    Murray MY, Zaitseva L, Auger MJ, et al. · Cell Cycle · 2016 · Background
    PubMed: PMID 25565020 · NCT03702725 · Multiple Myeloma
  14. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
    Leonard JP, Jung SH, Johnson J, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26304886 · NCT02446236 · Lymphoma, Mantle-Cell
  15. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.
    Lee SJ, Wolff D, Kitko C, et al. · Biol Blood Marrow Transplant · 2016 · Background
    PubMed: PMID 25796139 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  16. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D, Di Liberto M, Martin P, et al. · Cancer Discov · 2016 · Background
    PubMed: PMID 25082755 · NCT03478514 · Lymphoma, Mantle-Cell

2015 (17 papers)

  1. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
    Wilson WH, Young RM, Schmitz R, et al. · Nat Med · 2015 · Derived
    PubMed: PMID 26193343 · NCT01325701 · Lymphoma, Large B-Cell, Diffuse
  2. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E, Leclercq L, de Jong J, et al. · Drug Metab Dispos · 2015 · Derived
    PubMed: PMID 25488930 · NCT01674322
  3. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.
    Yang Y, Shi J, Gu Z, et al. · Cancer Res · 2015 · Background
    PubMed: PMID 25589346 · NCT03702725 · Multiple Myeloma
  4. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y, Zhang LL, Champlin RE, et al. · Clin Pharmacol Ther · 2015 · Background
    PubMed: PMID 25669675 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  5. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.
    Vater I, Montesinos-Rongen M, Schlesner M, et al. · Leukemia · 2015 · Background
    PubMed: PMID 25189415 · NCT04066920
  6. B cells in chronic graft-versus-host disease.
    Sarantopoulos S, Blazar BR, Cutler C, et al. · Biol Blood Marrow Transplant · 2015 · Background
    PubMed: PMID 25452031 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  7. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
    Reynaud Q, Durieu I, Dutertre M, et al. · Autoimmun Rev · 2015 · Background
    PubMed: PMID 25497766 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  8. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
    Quinquenel A, Willekens C, Dupuis J, et al. · Am J Hematol · 2015 · Background
    PubMed: PMID 25428829 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  9. Update on ibrutinib.
    O'Brien SM · Clin Adv Hematol Oncol · 2015 · Background
    PubMed: PMID 24896547 · NCT02446236 · Lymphoma, Mantle-Cell
  10. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
    Manda S, Dunbar N, Marx-Wood CR, et al. · Br J Haematol · 2015 · Background
    PubMed: PMID 25716177 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  11. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
    Jagasia MH, Greinix HT, Arora M, et al. · Biol Blood Marrow Transplant · 2015 · Background
    PubMed: PMID 25529383 · NCT03267186 · Leukemia, Myeloid, Acute
  12. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
    Farooqui MZ, Valdez J, Martyr S, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25555420 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  13. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia.
    Dierickx D, Kentos A, Delannoy A, et al. · Blood · 2015 · Background
    PubMed: PMID 25827833 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  14. NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD.
    Curtis LM, Grkovic L, Mitchell SA, et al. · Bone Marrow Transplant · 2015 · Background
    PubMed: PMID 25153693 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  15. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
    Cheson BD, Fisher RI, Barrington SF, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 25113753 · NCT05431179 · Lymphoma, Mantle-Cell
  16. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Byrd JC, Furman RR, Coutre SE, et al. · Blood · 2015 · Background
    PubMed: PMID 25700432 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  17. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    Burger JA, Keating MJ, Wierda WG, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25150798 · NCT03689894 · Bronchiolitis Obliterans Syndrome

2014 (13 papers)

  1. Sources of interindividual variability.
    Thummel KE, Lin YS · Methods Mol Biol · 2014 · Trial result
    PubMed: PMID 24523121 · NCT04522284 · Waldenstrom Macroglobulinemia
  2. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    Byrd JC, Brown JR, O'Brien S, et al. · N Engl J Med · 2014 · Derived
    PubMed: PMID 24881631 · NCT01578707 (RESONATE™) · Leukemia, Lymphocytic, Chronic, B-Cell
  3. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
    Zinzani PL, Vose JM, Czuczman MS, et al. · Ann Oncol · 2014 · Background
    PubMed: PMID 24030098 · NCT02446236 · Lymphoma, Mantle-Cell
  4. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
    Woyach JA, Smucker K, Smith LL, et al. · Blood · 2014 · Background
    PubMed: PMID 24415539 · NCT02446236 · Lymphoma, Mantle-Cell
  5. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
    Wodarz D, Garg N, Komarova NL, et al. · Blood · 2014 · Background
    PubMed: PMID 24829205 · NCT02446236 · Lymphoma, Mantle-Cell
  6. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.
    Mathews Griner LA, Guha R, Shinn P, et al. · Proc Natl Acad Sci U S A · 2014 · Background
    PubMed: PMID 24469833 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  7. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S, Marturano E, Licata G, et al. · Hematol Oncol · 2014 · Background
    PubMed: PMID 23161567 · NCT04066920
  8. Graft-versus-host disease: why have we not made more progress?
    Jaglowski SM, Devine SM · Curr Opin Hematol · 2014 · Background
    PubMed: PMID 24468835 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  9. Targeting Bruton's tyrosine kinase in B cell malignancies.
    Hendriks RW, Yuvaraj S, Kil LP, et al. · Nat Rev Cancer · 2014 · Background
    PubMed: PMID 24658273 · NCT02446236 · Lymphoma, Mantle-Cell
  10. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies.
    Hallek M · Blood · 2014 · Background
    PubMed: PMID 24065239 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  11. [National guidelines for the management of patients with chronic lymphocytic leukemia. Sociedad Espan˜ola de Hematologı´a y Hemoterapia and Grupo Espan˜ol de Leucemia Linfocı´tica Cro´ nica].
    García Marco JA, Giraldo Castellano P, López Jiménez J, et al. · Med Clin (Barc) · 2014 · Background
    PubMed: PMID 23830547 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell
  12. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
    Furman RR, Sharman JP, Coutre SE, et al. · N Engl J Med · 2014 · Background
    PubMed: PMID 24450857 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  13. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
    Cartron G, de Guibert S, Dilhuydy MS, et al. · Blood · 2014 · Background
    PubMed: PMID 25143487 · NCT03755947 · Leukemia, Lymphocytic, Chronic, B-Cell

2013 (18 papers)

  1. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    Wang ML, Rule S, Martin P, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23782157 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  2. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
    Wang M, Fowler N, Wagner-Bartak N, et al. · Leukemia · 2013 · Background
    PubMed: PMID 23545991 · NCT02446236 · Lymphoma, Mantle-Cell
  3. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.
    Vegliante MC, Palomero J, Pérez-Galán P, et al. · Blood · 2013 · Background
    PubMed: PMID 23321250 · NCT02446236 · Lymphoma, Mantle-Cell
  4. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
    Vander Lugt MT, Braun TM, Hanash S, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23924003 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  5. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
    Rushworth SA, Bowles KM, Barrera LN, et al. · Cell Signal · 2013 · Background
    PubMed: PMID 22975686 · NCT03702725 · Multiple Myeloma
  6. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ, Niederle N, Maschmeyer G, et al. · Lancet · 2013 · Background
    PubMed: PMID 23433739 · NCT02446236 · Lymphoma, Mantle-Cell
  7. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.
    Rickert RC · Nat Rev Immunol · 2013 · Background
    PubMed: PMID 23883968 · NCT02446236 · Lymphoma, Mantle-Cell
  8. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia.
    Maura F, Visco C, Falisi E, et al. · Am J Hematol · 2013 · Background
    PubMed: PMID 23115077 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  9. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.
    Lyman GH, Khorana AA, Kuderer NM, et al. · J Clin Oncol · 2013 · Background
    PubMed: PMID 23669224 · NCT02446236 · Lymphoma, Mantle-Cell
  10. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
    Goy A, Sinha R, Williams ME, et al. · J Clin Oncol · 2013 · Background
    PubMed: PMID 24002500 · NCT02446236 · Lymphoma, Mantle-Cell
  11. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
    Dubovsky JA, Beckwith KA, Natarajan G, et al. · Blood · 2013 · Background
    PubMed: PMID 23886836 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  12. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
    Cutler C, Kim HT, Bindra B, et al. · Blood · 2013 · Background
    PubMed: PMID 23861248 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  13. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
    Chang BY, Francesco M, De Rooij MF, et al. · Blood · 2013 · Background
    PubMed: PMID 23940282 · NCT03702725 · Multiple Myeloma
  14. Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.
    Caballero D, Campo E, López-Guillermo A, et al. · Ann Hematol · 2013 · Background
    PubMed: PMID 23716187 · NCT02446236 · Lymphoma, Mantle-Cell
  15. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    Byrd JC, Furman RR, Coutre SE, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23782158 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  16. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.
    Birnbaum T, Stadler EA, von Baumgarten L, et al. · J Neurooncol · 2013 · Background
    PubMed: PMID 22570142 · NCT04066920
  17. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
    Bam R, Ling W, Khan S, et al. · Am J Hematol · 2013 · Background
    PubMed: PMID 23456977 · NCT03702725 · Multiple Myeloma
  18. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Advani RH, Buggy JJ, Sharman JP, et al. · J Clin Oncol · 2013 · Background
    PubMed: PMID 23045577 · NCT03689894 · Bronchiolitis Obliterans Syndrome

2012 (12 papers)

  1. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
    Yang Y, Shaffer AL, Emre NC, et al. · Cancer Cell · 2012 · Background
    PubMed: PMID 22698399 · NCT03702725 · Multiple Myeloma
  2. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM · Am J Hematol · 2012 · Background
    PubMed: PMID 22615102 · NCT02446236 · Lymphoma, Mantle-Cell
  3. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
    Siegel DS, Martin T, Wang M, et al. · Blood · 2012 · Background
    PubMed: PMID 22833546 · NCT03702725 · Multiple Myeloma
  4. Non-Hodgkin lymphoma.
    Shankland KR, Armitage JO, Hancock BW, et al. · Lancet · 2012 · Background
    PubMed: PMID 22835603 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  5. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
    Roberts AW, Seymour JF, Brown JR, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22184378 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  6. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Ponader S, Chen SS, Buggy JJ, et al. · Blood · 2012 · Background
    PubMed: PMID 22180443 · NCT02446236 · Lymphoma, Mantle-Cell
  7. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
    Leonard JP, LaCasce AS, Smith MR, et al. · Blood · 2012 · Background
    PubMed: PMID 22383795 · NCT03478514 · Lymphoma, Mantle-Cell
  8. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.
    LaCasce AS, Vandergrift JL, Rodriguez MA, et al. · Blood · 2012 · Background
    PubMed: PMID 22234679 · NCT02446236 · Lymphoma, Mantle-Cell
  9. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
    Kumar SK, Lee JH, Lahuerta JJ, et al. · Leukemia · 2012 · Background
    PubMed: PMID 21799510 · NCT03702725 · Multiple Myeloma
  10. Are we improving the survival of patients with mantle cell lymphoma: if so, what is the explanation?
    Goy A · Leuk Lymphoma · 2012 · Background
    PubMed: PMID 21767240 · NCT02446236 · Lymphoma, Mantle-Cell
  11. Mantle cell lymphoma: the promise of new treatment options.
    Goy A, Kahl B · Crit Rev Oncol Hematol · 2012 · Background
    PubMed: PMID 21168343 · NCT02446236 · Lymphoma, Mantle-Cell
  12. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.
    Arai S, Sahaf B, Narasimhan B, et al. · Blood · 2012 · Background
    PubMed: PMID 22563089 · NCT03689894 · Bronchiolitis Obliterans Syndrome

2011 (13 papers)

  1. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.
    Wolff D, Schleuning M, von Harsdorf S, et al. · Biol Blood Marrow Transplant · 2011 · Background
    PubMed: PMID 20685255 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  2. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
    Witzig TE, Vose JM, Zinzani PL, et al. · Ann Oncol · 2011 · Background
    PubMed: PMID 21228334 · NCT02446236 · Lymphoma, Mantle-Cell
  3. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.
    Villano JL, Koshy M, Shaikh H, et al. · Br J Cancer · 2011 · Background
    PubMed: PMID 21915121 · NCT04066920
  4. Biomarkers in chronic graft-versus-host disease.
    Rozmus J, Schultz KR · Expert Rev Hematol · 2011 · Background
    PubMed: PMID 21668397 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  5. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia.
    Rossignol J, Michallet AS, Oberic L, et al. · Leukemia · 2011 · Background
    PubMed: PMID 21127498 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  6. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo.
    Qian Z, Zhang L, Cai Z, et al. · Leuk Res · 2011 · Background
    PubMed: PMID 21047686 · NCT02446236 · Lymphoma, Mantle-Cell
  7. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
    Lopez-Girona A, Heintel D, Zhang LH, et al. · Br J Haematol · 2011 · Background
    PubMed: PMID 21707574 · NCT02446236 · Lymphoma, Mantle-Cell
  8. The tumor lysis syndrome.
    Howard SC, Jones DP, Pui CH, et al. · N Engl J Med · 2011 · Background
    PubMed: PMID 21561350 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  9. Chronic lymphocytic leukemia and autoimmunity: a systematic review.
    Hodgson K, Ferrer G, Montserrat E, et al. · Haematologica · 2011 · Background
    PubMed: PMID 21242190 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  10. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE, Gordon AL, Hertlein E, et al. · Blood · 2011 · Background
    PubMed: PMID 21422473 · NCT02446236 · Lymphoma, Mantle-Cell
  11. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F, Baz R · Blood Rev · 2011 · Background
    PubMed: PMID 21126632 · NCT02446236 · Lymphoma, Mantle-Cell
  12. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens.
    Braggio E, McPhail ER, Macon W, et al. · Clin Cancer Res · 2011 · Background
    PubMed: PMID 21562036 · NCT04066920
  13. Rituximab monotherapy for patients with recurrent primary CNS lymphoma.
    Batchelor TT, Grossman SA, Mikkelsen T, et al. · Neurology · 2011 · Background
    PubMed: PMID 21383331 · NCT04066920

2010 (6 papers)

  1. Incidence and risk factors of venous thromboembolic events in lymphoma.
    Zhou X, Teegala S, Huen A, et al. · Am J Med · 2010 · Background
    PubMed: PMID 20920696 · NCT02446236 · Lymphoma, Mantle-Cell
  2. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
    Tam CS, Khouri IF · Leuk Lymphoma · 2010 · Background
    PubMed: PMID 19562639 · NCT02446236 · Lymphoma, Mantle-Cell
  3. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.
    Ramsay AG, Clear AJ, Kelly G, et al. · Blood · 2010 · Background
    PubMed: PMID 19786615 · NCT02446236 · Lymphoma, Mantle-Cell
  4. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
    Rajkumar SV, Jacobus S, Callander NS, et al. · Lancet Oncol · 2010 · Background
    PubMed: PMID 19853510 · NCT03702725 · Multiple Myeloma
  5. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE, Ngo VN, Lenz G, et al. · Nature · 2010 · Background
    PubMed: PMID 20054396 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  6. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
    Coiffier B, Thieblemont C, Van Den Neste E, et al. · Blood · 2010 · Background
    PubMed: PMID 20548096 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse

2009 (8 papers)

  1. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
    Zhang L, Qian Z, Cai Z, et al. · Am J Hematol · 2009 · Background
    PubMed: PMID 19565649 · NCT02446236 · Lymphoma, Mantle-Cell
  2. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
    Richardson P, Jagannath S, Hussein M, et al. · Blood · 2009 · Background
    PubMed: PMID 19471019 · NCT03702725 · Multiple Myeloma
  3. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia.
    Kaufman M, Limaye SA, Driscoll N, et al. · Leuk Lymphoma · 2009 · Background
    PubMed: PMID 19391041 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  4. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
    Hess G, Herbrecht R, Romaguera J, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19581539 · NCT02446236 · Lymphoma, Mantle-Cell
  5. Improvement of overall survival in advanced stage mantle cell lymphoma.
    Herrmann A, Hoster E, Zwingers T, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19075279 · NCT03478514 · Lymphoma, Mantle-Cell
  6. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
    Habermann TM, Lossos IS, Justice G, et al. · Br J Haematol · 2009 · Background
    PubMed: PMID 19245430 · NCT02446236 · Lymphoma, Mantle-Cell
  7. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
    Goy A, Bernstein SH, Kahl BS, et al. · Ann Oncol · 2009 · Background
    PubMed: PMID 19074748 · NCT02446236 · Lymphoma, Mantle-Cell
  8. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Background
    PubMed: PMID 19097774 · NCT03702725 · Multiple Myeloma

2008 (13 papers)

  1. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
    Zhu D, Corral LG, Fleming YW, et al. · Cancer Immunol Immunother · 2008 · Background
    PubMed: PMID 18392823 · NCT02446236 · Lymphoma, Mantle-Cell
  2. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.
    Zhou Y, Wang H, Fang W, et al. · Cancer · 2008 · Background
    PubMed: PMID 18615506 · NCT02446236 · Lymphoma, Mantle-Cell
  3. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L, Adams M, Carter T, et al. · Clin Cancer Res · 2008 · Background
    PubMed: PMID 18628480 · NCT02446236 · Lymphoma, Mantle-Cell
  4. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH, Lossos IS, Tuscano JM, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18606983 · NCT02446236 · Lymphoma, Mantle-Cell
  5. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia.
    Thurmes P, Call T, Slager S, et al. · Leuk Lymphoma · 2008 · Background
    PubMed: PMID 18203011 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  6. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate.
    Reni M, Mazza E, Foppoli M, et al. · Cancer Lett · 2008 · Background
    PubMed: PMID 17993246 · NCT04066920
  7. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
    Hoster E, Dreyling M, Klapper W, et al. · Blood · 2008 · Background
    PubMed: PMID 17962512 · NCT02446236 · Lymphoma, Mantle-Cell
  8. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
    Hallek M, Cheson BD, Catovsky D, et al. · Blood · 2008 · Background
    PubMed: PMID 18216293 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  9. Direct multiplexed measurement of gene expression with color-coded probe pairs.
    Geiss GK, Bumgarner RE, Birditt B, et al. · Nat Biotechnol · 2008 · Background
    PubMed: PMID 18278033 · NCT03702725 · Multiple Myeloma
  10. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.
    Geisler CH, Kolstad A, Laurell A, et al. · Blood · 2008 · Background
    PubMed: PMID 18625886 · NCT02446236 · Lymphoma, Mantle-Cell
  11. Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push?
    Del Gaizo Moore V, Letai A · Adv Exp Med Biol · 2008 · Background
    PubMed: PMID 18437895 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  12. MiR-15a and miR-16-1 cluster functions in human leukemia.
    Calin GA, Cimmino A, Fabbri M, et al. · Proc Natl Acad Sci U S A · 2008 · Background
    PubMed: PMID 18362358 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  13. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
    Ansell SM, Inwards DJ, Rowland KM, et al. · Cancer · 2008 · Background
    PubMed: PMID 18543327 · NCT02446236 · Lymphoma, Mantle-Cell

2007 (12 papers)

  1. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    Weber DM, Chen C, Niesvizky R, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 18032763 · NCT03702725 · Multiple Myeloma
  2. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
    Verhelle D, Corral LG, Wong K, et al. · Cancer Res · 2007 · Background
    PubMed: PMID 17234786 · NCT02446236 · Lymphoma, Mantle-Cell
  3. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
    Richardson PG, Blood E, Mitsiades CS, et al. · Blood · 2007 · Background
    PubMed: PMID 16840727 · NCT03702725 · Multiple Myeloma
  4. Temozolomide as salvage treatment in primary brain lymphomas.
    Reni M, Zaja F, Mason W, et al. · Br J Cancer · 2007 · Background
    PubMed: PMID 17325700 · NCT04066920
  5. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials.
    Pavletic SZ, Lee SJ, Socie G, et al. · Bone Marrow Transplant · 2007 · Background
    PubMed: PMID 16980994 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  6. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
    Hillmen P, Skotnicki AB, Robak T, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17984186 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  7. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW, Neuberg DS, Grever MR, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17283364 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  8. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M, Spencer A, Attal M, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 18032762 · NCT03702725 · Multiple Myeloma
  9. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
    Del Gaizo Moore V, Brown JR, Certo M, et al. · J Clin Invest · 2007 · Background
    PubMed: PMID 17200714 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  10. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
    D'Arena G, Laurenti L, Capalbo S, et al. · Am J Hematol · 2007 · Background
    PubMed: PMID 16823816 · NCT03469895 (CABRI) · Leukemia, Lymphocytic, Chronic, B-Cell
  11. Revised response criteria for malignant lymphoma.
    Cheson BD, Pfistner B, Juweid ME, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17242396 · NCT03088878 · Leukemia, Lymphocytic, Chronic, B-Cell
  12. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
    Catovsky D, Richards S, Matutes E, et al. · Lancet · 2007 · Background
    PubMed: PMID 17658394 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse

2006 (14 papers)

  1. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
    Smith TJ, Khatcheressian J, Lyman GH, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16682719 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  2. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
    Pfreundschuh M, Trümper L, Osterborg A, et al. · Lancet Oncol · 2006 · Background
    PubMed: PMID 16648042 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  3. Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index.
    Møller MB, Pedersen NT, Christensen BE, et al. · Br J Haematol · 2006 · Background
    PubMed: PMID 16512827 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  4. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
    Marzec M, Kasprzycka M, Lai R, et al. · Blood · 2006 · Background
    PubMed: PMID 16690963 · NCT03478514 · Lymphoma, Mantle-Cell
  5. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
    Küker W, Nägele T, Thiel E, et al. · Neurology · 2006 · Background
    PubMed: PMID 16217075 · NCT04066920
  6. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma.
    Katzenberger T, Petzoldt C, Höller S, et al. · Blood · 2006 · Background
    PubMed: PMID 16597597 · NCT02446236 · Lymphoma, Mantle-Cell
  7. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
    Habermann TM, Weller EA, Morrison VA, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16754935 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  8. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
    Fisher RI, Bernstein SH, Kahl BS, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 17001068 · NCT02446236 · Lymphoma, Mantle-Cell
  9. Prospective trial on topotecan salvage therapy in primary CNS lymphoma.
    Fischer L, Thiel E, Klasen HA, et al. · Ann Oncol · 2006 · Background
    PubMed: PMID 16603598 · NCT04066920
  10. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.
    Filipovich AH, Weisdorf D, Pavletic S, et al. · Biol Blood Marrow Transplant · 2006 · Background
    PubMed: PMID 16338616 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  11. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
    Eichhorst BF, Busch R, Hopfinger G, et al. · Blood · 2006 · Background
    PubMed: PMID 16219797 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  12. International uniform response criteria for multiple myeloma.
    Durie BG, Harousseau JL, Miguel JS, et al. · Leukemia · 2006 · Background
    PubMed: PMID 16855634 · NCT03702725 · Multiple Myeloma
  13. Rituximab for steroid-refractory chronic graft-versus-host disease.
    Cutler C, Miklos D, Kim HT, et al. · Blood · 2006 · Background
    PubMed: PMID 16551963 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  14. Immunomodulatory drugs.
    Crane E, List A · Cancer Invest · 2006 · Background
    PubMed: PMID 16305990 · NCT02446236 · Lymphoma, Mantle-Cell

2005 (7 papers)

  1. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
    Witzig TE, Geyer SM, Ghobrial I, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15983389 · NCT02446236 · Lymphoma, Mantle-Cell
  2. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
    Sehn LH, Donaldson J, Chhanabhai M, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15955905 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  3. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
    Romaguera JE, Fayad L, Rodriguez MA, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 16145068 · NCT02446236 · Lymphoma, Mantle-Cell
  4. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
    Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. · Clin Cancer Res · 2005 · Background
    PubMed: PMID 16115943 · NCT02446236 · Lymphoma, Mantle-Cell
  5. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Goy A, Younes A, McLaughlin P, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15613697 · NCT02446236 · Lymphoma, Mantle-Cell
  6. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Feugier P, Van Hoof A, Sebban C, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15867204 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  7. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.
    Dredge K, Horsfall R, Robinson SP, et al. · Microvasc Res · 2005 · Background
    PubMed: PMID 15797261 · NCT02446236 · Lymphoma, Mantle-Cell

2004 (3 papers)

  1. Overexpression of Bcl-W in the testis disrupts spermatogenesis: revelation of a role of BCL-W in male germ cell cycle control.
    Yan W, Huang JX, Lax AS, et al. · Mol Endocrinol · 2004 · Background
    PubMed: PMID 12808071 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  2. Tumour lysis syndrome: new therapeutic strategies and classification.
    Cairo MS, Bishop M · Br J Haematol · 2004 · Background
    PubMed: PMID 15384972 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  3. Antigen-specific B-lymphocyte activation.
    Bishop GA, Haxhinasto SA, Stunz LL, et al. · Crit Rev Immunol · 2004 · Background
    PubMed: PMID 14584878 · NCT03702725 · Multiple Myeloma

2003 (8 papers)

  1. Lymphoid malignancies: the dark side of B-cell differentiation.
    Shaffer AL, Rosenwald A, Staudt LM, et al. · Nat Rev Immunol · 2003 · Background
    PubMed: PMID 12461565 · NCT02446236 · Lymphoma, Mantle-Cell
  2. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.
    Schafer PH, Gandhi AK, Loveland MA, et al. · J Pharmacol Exp Ther · 2003 · Background
    PubMed: PMID 12649301 · NCT02446236 · Lymphoma, Mantle-Cell
  3. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.
    Rosenwald A, Wright G, Wiestner A, et al. · Cancer Cell · 2003 · Background
    PubMed: PMID 12620412 · NCT02446236 · Lymphoma, Mantle-Cell
  4. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.
    Lee Sk, Cook EF, Soiffer R, et al. · Biol Blood Marrow Transplant · 2003 · Background
    PubMed: PMID 12234170 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  5. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002.
    Ferreri AJ, Abrey LE, Blay JY, et al. · J Clin Oncol · 2003 · Background
    PubMed: PMID 12805341 · NCT04066920
  6. The Bcl-2 family: roles in cell survival and oncogenesis.
    Cory S, Huang DC, Adams JM, et al. · Oncogene · 2003 · Background
    PubMed: PMID 14634621 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  7. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions.
    Borner C · Mol Immunol · 2003 · Background
    PubMed: PMID 12493639 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  8. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
    Arellano-Rodrigo E, López-Guillermo A, Bessell EM, et al. · Eur J Haematol · 2003 · Background
    PubMed: PMID 12656744 · NCT04066920

2002 (4 papers)

  1. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
    Rosenwald A, Wright G, Chan WC, et al. · N Engl J Med · 2002 · Background
    PubMed: PMID 12075054 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  2. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
    Marriott JB, Clarke IA, Dredge K, et al. · Clin Exp Immunol · 2002 · Background
    PubMed: PMID 12296856 · NCT02446236 · Lymphoma, Mantle-Cell
  3. The Bcl2 family: regulators of the cellular life-or-death switch.
    Cory S, Adams JM · Nat Rev Cancer · 2002 · Background
    PubMed: PMID 12209154 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B, Lepage E, Briere J, et al. · N Engl J Med · 2002 · Background
    PubMed: PMID 11807147 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse

2001 (6 papers)

  1. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM, Link BK, Grossbard ML, et al. · J Clin Oncol · 2001 · Background
    PubMed: PMID 11208830 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  2. Bcl-2 inhibits apoptosis of spermatogonia and growth of spermatogonial stem cells in a cell-intrinsic manner.
    Sugiyama N, Obinata M, Matsui Y, et al. · Mol Reprod Dev · 2001 · Background
    PubMed: PMID 11144217 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  3. Expression of Bcl-2 family proteins and spontaneous apoptosis in normal human testis.
    Oldereid NB, Angelis PD, Wiger R, et al. · Mol Hum Reprod · 2001 · Background
    PubMed: PMID 11331661 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  4. Morphological and immunophenotypic features of chronic lymphocytic leukemia.
    Matutes E, Polliack A · Rev Clin Exp Hematol · 2001 · Background
    PubMed: PMID 11486329 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  5. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
    Leporrier M, Chevret S, Cazin B, et al. · Blood · 2001 · Background
    PubMed: PMID 11588025 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  6. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.
    Fry DW, Bedford DC, Harvey PH, et al. · J Biol Chem · 2001 · Background
    PubMed: PMID 11278443 · NCT03478514 · Lymphoma, Mantle-Cell

2000 (4 papers)

  1. A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase.
    Satterthwaite AB, Willis F, Kanchanastit P, et al. · Proc Natl Acad Sci U S A · 2000 · Background
    PubMed: PMID 10829070 · NCT02446236 · Lymphoma, Mantle-Cell
  2. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    Rai KR, Peterson BL, Appelbaum FR, et al. · N Engl J Med · 2000 · Background
    PubMed: PMID 11114313 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  3. When and how to treat chronic lymphocytic leukemia.
    Dighiero G, Binet JL · N Engl J Med · 2000 · Background
    PubMed: PMID 11114321 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  4. Immunomodulation by thalidomide and thalidomide analogues.
    Corral LG, Kaplan G · Ann Rheum Dis · 2000 · Background
    PubMed: PMID 10577986 · NCT02446236 · Lymphoma, Mantle-Cell

1999 (2 papers)

  1. BCL-2 gene family and the regulation of programmed cell death.
    Korsmeyer SJ · Cancer Res · 1999 · Background
    PubMed: PMID 10197582 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  2. Management of mantle cell lymphoma.
    Armitage JO · Oncology (Williston Park) · 1999 · Background
    PubMed: PMID 9830633 · NCT02446236 · Lymphoma, Mantle-Cell

1997 (2 papers)

  1. Cancer burden in the aged: an epidemiologic and demographic overview.
    Yancik R · Cancer · 1997 · Background
    PubMed: PMID 9317180 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  2. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale.
    McQuellon RP, Russell GB, Cella DF, et al. · Bone Marrow Transplant · 1997 · Background
    PubMed: PMID 9051246 · NCT03689894 · Bronchiolitis Obliterans Syndrome

1996 (3 papers)

  1. Graft-versus-host disease and the Th1/Th2 paradigm.
    Krenger W, Ferrara JL · Immunol Res · 1996 · Background
    PubMed: PMID 8739565 · NCT03689894 · Bronchiolitis Obliterans Syndrome
  2. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
    Johnson S, Smith AG, Löffler H, et al. · Lancet · 1996 · Background
    PubMed: PMID 8676625 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse
  3. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
    Cheson BD, Bennett JM, Grever M, et al. · Blood · 1996 · Background
    PubMed: PMID 8652811 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse

1995 (1 paper)

  1. Growth suppression by p16ink4 requires functional retinoblastoma protein.
    Medema RH, Herrera RE, Lam F, et al. · Proc Natl Acad Sci U S A · 1995 · Background
    PubMed: PMID 7603984 · NCT03478514 · Lymphoma, Mantle-Cell

1994 (1 paper)

  1. Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic.
    Weisenburger DD · Ann Oncol · 1994 · Background
    PubMed: PMID 8172811 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse

1988 (1 paper)

  1. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation.
    Shustik C, Mick R, Silver R, et al. · Hematol Oncol · 1988 · Background
    PubMed: PMID 3277904 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse

1983 (1 paper)

  1. Toxicity and response criteria of the Eastern Cooperative Oncology Group.
    Oken MM, Creech RH, Tormey DC, et al. · Am J Clin Oncol · 1983 · Background
    PubMed: PMID 7165009 · NCT03702725 · Multiple Myeloma

1981 (1 paper)

  1. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.
    Binet JL, Auquier A, Dighiero G, et al. · Cancer · 1981 · Background
    PubMed: PMID 7237385 · NCT03136497 · Lymphoma, Large B-Cell, Diffuse

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).